<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0510234305
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2023
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Triplixam
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        PERINDOPRIL ARGININE,INDAPAMIDE,AMLODIPINE BESILATE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        5,1.25,10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Bottle
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        94.95
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="SERVIER" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            SERVIER
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 4377]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Servier Saudi Arabia Trading LLC
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            LES LABORATOIRES SERVIER 
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        C09BX01
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Triplixam is a combination of three active ingredients: perindopril, indapamide and amlodipine. It is an anti-hypertensive medicine used in the treatment of high blood pressure (hypertension).</p><p>&nbsp;</p><p>Patients already taking perindopril/indapamide as fixed dose combination and amlodipine from separate tablets may instead receive one tablet of Triplixam which contains the three active ingredients in the same strength.</p><p><strong>&nbsp;</strong></p><p>Each of the active ingredients reduces blood pressure and they work together to control your blood pressure:</p><p>- Perindopril belongs to a class of medicines called Angiotensin Converting Enzyme (ACE) inhibitors. It works by widening the blood vessels, which makes it easier for your heart to pump blood through them.</p><p>- Indapamide is a diuretic (which belongs to a class of medicines called sulfonamide derivatives with an indole ring). Diuretics increase the amount of urine produced by the kidneys. However, indapamide is different from other diuretics, as it only causes a slight increase in the amount of urine produced.</p><p>- Amlodipine is a calcium channel blockers (which belongs to a class of medicines called dihydropyridines). It works by relaxing blood vessels, so blood passes through easily.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take </strong><strong>Triplixam</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are allergic to perindopril or other ACE-inhibitors, indapamide or other sulfonamides, amlodipine or other dihydropyridines, or any of the other ingredients of this medicine (listed in Section 6),</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have experienced symptoms such as wheezing, swelling of the face or tongue, intense itching or severe skin rashes with previous ACE inhibitor treatment or if you or a member of your family have had these symptoms in any other circumstances (a condition called angioedema),</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have severe liver disease or suffer from a condition called hepatic encephalopathy (disease of the brain caused by liver illness),</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are suspected of having untreated decompensated heart failure (severe water retention, difficulty in breathing),</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have narrowing of the aortic heart valve (aortic stenosis) or cardiogenic shock (a condition where your heart is unable to supply enough blood to the body),</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you suffer from heart failure after a heart attack,</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have severe low blood pressure (hypotension),</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have low blood potassium,</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have severe kidney problems where the blood supply to your kidneys is reduced (renal artery stenosis),</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are receiving dialysis or any other type of blood filtration. Depending on the machine that is used, Triplixam may not be suitable for you,</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you&nbsp; have moderate kidney problems (for Triplixam doses containing 10mg/2.5mg/5mg and 10mg/2.5mg/10mg),</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are more than 3 months pregnant (it is also better to avoid Triplixam in early pregnancy &ndash; see pregnancy section.),</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have diabetes or impaired kidney function and you are treated with a blood pressure lowering medicine containing aliskiren,</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have taken or are currently taking sacubitril/valsartan, a medicine for heart failure, as the risk of angioedema (rapid swelling under the skin in an area such as the throat) is increased (see &ldquo;Warning and Precaution&rdquo; and &ldquo;Other medicines and Triplixam&rdquo;).</p><p>&nbsp;</p><p><strong>Warnings and precautions</strong></p><p>Talk to your doctor or pharmacist before taking Triplixam:</p><p>-&nbsp;&nbsp;&nbsp; if you have hypertrophic cardiomyopathy (heart muscle disease) or renal artery stenosis (narrowing of the artery supplying the kidney with blood),</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have heart failure or any other heart problems,</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have severe increase in blood pressure (hypertensive crisis),</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have liver problems,</p><p>-&nbsp;&nbsp;&nbsp; if you suffer from a collagen disease (skin disease) such as systemic lupus erythematosus or scleroderma,</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have atherosclerosis (hardening of the arteries),</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you need to have a test to check how well your parathyroid gland is working,</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you suffer from gout,</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have diabetes,</p><p>-&nbsp;&nbsp;&nbsp; if you are on a salt restricted diet or use salt substitutes which contain potassium (a well-balanced potassium blood level is essential),</p><p>-&nbsp;&nbsp;&nbsp; if you take lithium or potassium-sparing diuretics (spironolactone, triamterene) as their use with Triplixam should be avoided (see &ldquo;Taking other medicines&rdquo;),</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are elderly and your dose needs to be increased,</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have had photosensitivity reactions,</p><p>-&nbsp;&nbsp;&nbsp; if you are black origin you may have higher incidence of angiodema (swelling of the face, lips, mouth, tongue or throat which may cause difficulty in swallowing or breathing) and less effective in lowering blood pressure,</p><p>-&nbsp;&nbsp;&nbsp; if you are Haemodialysis patients dialysed with high-flux membranes,</p><p>-&nbsp;&nbsp;&nbsp; if you have kidney problems or if you are receiving dialysis,</p><p>-&nbsp;&nbsp;&nbsp; if you experience a decrease in vision or eye pain. These could be symptoms of fluid accumulation in the vascular layer of the eye (choroidal effusion) or an increase of pressure in your eye and can happen within hours to&nbsp; weeks of taking Triplixam. This can lead to permanent vision loss, if not treated. If you earlier have had a penicillin or sulfonamide allergy, you can be at higher risk of developing this,</p><p>-&nbsp;&nbsp;&nbsp; if you have muscle disorders including muscle pain, tenderness, weakness or cramps,</p><p>-&nbsp;&nbsp;&nbsp; if you have abnormally increased levels of a hormone called aldosterone in your blood (primary aldosteronism),</p><p>-&nbsp;&nbsp;&nbsp; if you have too much acid in blood, which may cause an increased rate of breathing,</p><p>-&nbsp;&nbsp;&nbsp; if you have cerebral circulatory insufficiency (low blood pressure in the brain),</p><p>-&nbsp;&nbsp;&nbsp; if you have swelling of the face, lips, mouth , tongue or throat which may cause difficulty in swallowing or breathing (angioedema), which can occur at any time during treatment, stop your treatment immediately and directly contact your doctor.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are taking any of the following medicines, the risk of angioedema is increased:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; racecadotril (used to treat diarrhea),</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sirolimus, everolimus, temsirolimus and other drugs belonging to the class of so-called mTor inhibitors (used to avoid rejection of transplanted organs and for cancer),</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sacubitril (available as fixed-dose combination with valsartan), used to treat long-term heart failure</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; linagliptin, saxagliptin, sitagliptin, vildagliptin and other drugs belonging to the class of the also called gliptins (used to treat diabetes).</p><p>-&nbsp;&nbsp;&nbsp; if you are taking any of the following medicines used to treat high blood pressure:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; an &ldquo;angiotensin II receptor blocker&rdquo; (ARBs) (also known as sartans - for example valsartan, telmisartan, irbesartan), in particular if you have diabetes-related kidney problems.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; aliskiren.</p><p>Your doctor may check your kidney function, blood pressure, and the amount of electrolytes (e.g. potassium) in your blood at regular intervals.</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; See also information under the heading &ldquo;Do not take Triplixam&rdquo;.</p><p>&nbsp;</p><p>&nbsp;</p><p>Your doctor may prescribe you blood tests to check for low sodium or potassium levels or high calcium levels.</p><p>&nbsp;</p><p>You must tell your doctor if you think that you are (<u>or might become</u>) pregnant. Triplixam is not recommended in early pregnancy, and must not be taken if you are more than 3 months pregnant, as it may cause serious harm to your baby if used at that stage (see &ldquo;Pregnancy and breastfeeding&rdquo;).</p><p>&nbsp;</p><p>When you are taking Triplixam, you should also inform your doctor or the medical staff:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are to undergo anaesthesia and/or surgery,</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have recently suffered from diarrhoea or vomiting, or are dehydrated,</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are to undergo dialysis or LDL apheresis (which is removal of cholesterol from your blood by a machine),</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are going to have desensitisation treatment to reduce the effects of an allergy to bee or wasp stings,</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are to undergo a medical test that requires injection of an iodinated contrast agent (a substance that makes organs like kidney or stomach visible on an X-ray).</p><p>&nbsp;</p><p>Athletes should be aware that Triplixam contains an active ingredient (indapamide) which may give a positive reaction in drug tests.</p><p>&nbsp;</p><p><strong>Children and adolescents</strong></p><p>Triplixam should not be given to children and adolescents.</p><p>&nbsp;</p><p><strong>Other medicines and Triplixam</strong></p><p>Please tell your doctor or pharmacist if you are taking or have recently taken or might take any other medicines.</p><p>&nbsp;</p><p>Do not take aliskiren (used to treat high blood pressure) if you have diabetes or kidney problems.</p><p>&nbsp;</p><p>You should avoid Triplixam with:</p><p>&uuml;&nbsp; lithium (used to treat some mental health disorders such as mania, manic depressive illness and recurrent depression),</p><p>&uuml;&nbsp; potassium-sparing drugs (e.g. triamterene, amiloride), potassium supplements or potassium-containing salt substitutes, other drugs which can increase potassium in your body (such as heparin, a medicine used to thin blood to prevent clots; &nbsp;trimethoprim and co-trimoxazole also known as trimethoprim/sulfamethoxazole for infections caused by bacteria),</p><p>&uuml;&nbsp; dantrolene (infusion) is also used to treat malignant hyperthermia during anaesthesia (symptoms including very high fever and muscle stiffness),</p><p>&uuml;&nbsp; estramustine (used in cancer therapy),</p><p>&uuml;&nbsp; medicines, which are most often used to treat diarrhea (racecadotril) or avoid rejection of transplanted organs (sirolimus, everolimus, temsirolimus and other drugs belonging to the class of so-called mTor inhibitors). See section &ldquo;Warnings and precautions&rdquo;,</p><p>&uuml;&nbsp; sacubitril/valsartan (used to treat long-term heart failure). See sections &ldquo;Do not take Triplixam&rdquo; and &ldquo;Warnings and precautions&rdquo;,</p><p>&uuml;&nbsp; other medicines used to treat high blood pressure: angiotensin-converting-enzyme inhibitor and angiotensin receptor blockers.</p><p>&nbsp;</p><p>Treatment with Triplixam can be affected by other medicines. Your doctor may need to change your dose and/or to take other precautions. Make sure to tell your doctor if you are taking any of the following medicines as special care may be required:</p><p>&uuml;&nbsp; other medicines for treating high blood pressure, including angiotensin II receptor blocker (ARB), aliskiren (see also information under the headings &ldquo;Do not take Triplixam&rdquo; and &ldquo;Warning and precaution&rdquo;), or diuretics (medicines which increase the amount of urine produced by the kidneys),</p><p>&uuml;&nbsp; potassium-sparing drugs used in the treatment of heart failure : eplerenone and spironolactone at doses between 12,5mg to 50mg per day,</p><p>&uuml;&nbsp; anaesthetic medicines</p><p>&uuml;&nbsp; iodinated contrast agent</p><p>&uuml;&nbsp; bepridil (used to treat angina pectoris),</p><p>&uuml;&nbsp; methadone (used to treat addiction)</p><p>&uuml;&nbsp; medicines used for heart rythm problems (e.g<strong> </strong>dofetilide, ibutilide, bretylium, cisapride, diphemamil, procainamide, quinidine, hydroquinidine, disopyramide, amiodarone, sotalol),</p><p>&uuml;&nbsp; verapamil, diltiazem (heart medicines)</p><p>&uuml;&nbsp; digoxin or other cardiac glycosides (for the treatment of heart problems),</p><p>&uuml;&nbsp; antibiotics used to treat bacterial infections (e.g<strong> </strong>rifampicin, erythromycin, clarithromycin, sparfloxacin, moxifloxacin),<strong>&nbsp; </strong></p><p>&uuml;&nbsp; antifungal medicines (e.g itraconazole, ketoconazole, amphotericin B by injection),</p><p>&uuml;&nbsp; allopurinol (for the treatment of gout),</p><p>&uuml;&nbsp; antihistamines used to treat allergic reactions such as hay fever (e.g. mizolastine, terfenadine,&nbsp; astemizole),</p><p>&uuml;&nbsp; corticosteroids used to treat various conditions including severe asthma and rheumatoid arthritis, and non-steroidal anti-inflammatory drugs (e.g. ibuprofen) or high dose salicylates (e.g. acetylsalicylic acid, &nbsp;a substance presents in many medicines used to relieve pain and lower fever, as well as to prevent blood clotting),</p><p>&uuml;&nbsp; immunosuppressants (medicines used to control your body&rsquo;s immune response) for the treatment of auto-immune disorders or following transplant surgery (e.g. ciclosporin, tacrolimus),</p><p>&uuml;&nbsp; tetracosactide (to treat Crohn&rsquo;s disease)</p><p>&uuml;&nbsp; gold salts, especially with intravenous administration (used to treat symptoms of rheumatoid arthritis),</p><p>&uuml;&nbsp; halofantrine (used to treat certain types of malaria),</p><p>&uuml;&nbsp; baclofen used to treat muscle stiffness in diseases such as multiple sclerosis,</p><p>&uuml;&nbsp; medicines to treat diabetes such as insulin or metformin,</p><p>&uuml;&nbsp; calcium including calcium supplements,</p><p>&uuml;&nbsp; stimulant laxatives (e.g. senna),</p><p>&uuml;&nbsp; medicines for the treatment of cancer,</p><p>&uuml;&nbsp; vincamine (used to treat symptomatic cognitive disorders in elderly including memory loss),</p><p>&uuml;&nbsp; medicines used to treat mental health disorders such as depression, anxiety, schizophrenia&hellip;(e.g. tricyclic antidepressants, antipsychotics, imipramine-like antidepressants, neuroleptics (such as amisulpride, sulpiride, sultopride, tiapride, haloperidol, droperidol)),</p><p>&uuml;&nbsp; pentamidine (used to treat pneumonia),</p><p>&uuml;&nbsp; ritonavir, indinavir, nelfinavir (so called protease inhibitors used to treat HIV),</p><p>&uuml;&nbsp; hypericum perforatum (St. John&rsquo;s Wort),</p><p>&uuml;&nbsp; trimethoprim (for the treatment of infections),</p><p>&uuml;&nbsp; medicines used for the treatment of low blood pressure, shock or asthma (<em>e.g.</em> ephedrine, noradrenaline or adrenaline),</p><p>&uuml;&nbsp; nitroglycerin and other nitrates, or other vasodilators that may further reduce blood pressure.</p><p>&nbsp;</p><p><strong>Triplixam</strong> <strong>with food and drink</strong></p><p>&nbsp;</p><p>Grapefruit juice and grapefruit should not be consumed by people who are taking Triplixam. This is because grapefruit and grapefruit juice can lead to an increase in the blood levels of the active ingredient amlodipine, which can cause an unpredictable increase in the blood pressure lowering effect of Triplixam.</p><p>&nbsp;</p><p><strong>Pregnancy and breast-feeding</strong></p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine</p><p>&nbsp;</p><p><strong>Pregnancy</strong></p><p>You must tell your doctor if you think that you are (<u>or might become</u>) pregnant.</p><p>Your doctor will normally advise you to stop taking Triplixam before you become pregnant or as soon as you know you are pregnant and will advise you to take another medicine instead of Triplixam. Triplixam is not recommended in early pregnancy, and must not be taken when more than 3 months pregnant, as it may cause serious harm to your baby if used after the third month of pregnancy.</p><p>&nbsp;</p><p><strong>Breast-feeding</strong></p><p><strong>Tell</strong> your doctor if you are breast-feeding or about to start breast-feeding. Triplixam is not recommended for mothers who are breast-feeding, and your doctor may choose another treatment for you if you wish to breast-feed, especially if your baby is new-born,&nbsp;or&nbsp;was&nbsp;born prematurely.</p><p>&nbsp;</p><p><strong>Driving and using machines</strong></p><p>Triplixam may affect your ability to drive or use machines. If the tablets make you feel sick, dizzy, tired, or give you a headache, do not drive or use machines and contact your doctor immediately.</p><p><strong>&nbsp;</strong></p><p><strong>Triplixam</strong><strong> </strong><strong>contains sodium</strong></p><p>Triplixam contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially &lsquo;sodium-free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.</p><p>Swallow the tablet with a glass of water preferably in the morning and before a meal. Your doctor will decide on the correct dose for you. This will normally be one tablet once a day.</p><p><strong>&nbsp;</strong></p><p><strong>If you take more </strong><strong>Triplixam </strong><strong>than you should</strong></p><p>Taking too many tablets may cause you blood pressure to become low or even dangerously low sometimes associated with nausea, vomiting, cramps, dizziness, sleepiness, mental confusion, oliguria (passing less urine than is normal), anuria (no production or passing of urine). You may feel lightheaded, faint, or weak. If blood pressure drop is severe enough shock can occur. Your skin could feel cool and clammy and you could lose consciousness.</p><p>Excess fluid may accumulate in your lungs (pulmonary oedema) causing shortness of breath that may develop up to 24-48 hours after intake. Seek immediate medical attention if you take too many Triplixam tablets.</p><p>&nbsp;</p><p><strong>If you forget to take </strong><strong>Triplixam</strong></p><p>It is important to take your medicine every day as regular treatment is more effective. However, If you forget to take a dose of Triplixam, take the next dose at the usual time. Do not take a double dose to make up for a forgotten dose.</p><p>&nbsp;</p><p><strong>If you stop taking </strong><strong>Triplixam</strong></p><p>As the treatment for high blood pressure is usually life-long, you should discuss with your doctor before stopping this medicinal product.</p><p>&nbsp;</p><p>If you have any further questions on the use of thismedicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p><strong>Stop taking the medicinal product and see a doctor immediately, if</strong> <strong>you experience any of the following</strong> <strong>side effects that can be serious</strong>:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sudden wheeziness, chest pain, shortness of breath, or difficulty in breathing, (Uncommon) (may affect up to 1 in 100 people)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swelling of eyelids, face or lips, (Uncommon) (may affect up to 1 in 100 people)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swelling of the mouth, tongue and throat, which causes great difficulty breathing, (Uncommon) (may affect up to 1 in 100 people)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; severe skin reactions including intense skin rash, hives, reddening of the skin over your whole body, severe itching, blistering, peeling and swelling of the skin, inflammation of mucous membranes (Stevens Johnson Syndrome, Toxic Epidermal Necrolysis) or other allergic reactions, (Very rare) (may affect up to 1 in 10,000 people)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; severe dizziness or fainting, (Common) (may affect up to 1 in 10 people)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; heart attack, (Very rare) (may affect up to 1 in 10,000 people), life-threatening irregular beat (Not known)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflamed pancreas which may cause severe abdominal and back pain accompanied with feeling very unwell (Very rare) (may affect up to 1 in 10,000 people)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; muscle weakness, cramps, tenderness or pain and particularly, if at the same time, you feel unwell or have a high temperature it may be caused by an abnormal muscle breakdown (not known).</p><p>&nbsp;</p><p>In decreasing order of frequency, side effects can include:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Very common (may affect more than 1 in 10 people):</p><p>Oedema (fluid retention).</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Common (may affect up to 1 in 10 people):</p><p>Low potassium in the blood,&nbsp;headache, dizziness, palpitations (awareness of your heartbeat), flushing, vertigo, pins and needles, visual impairment, double vision, tinnitus (sensation of noises in the ears), light-headedness due to low blood pressure, cough, shortness of breath, gastro-intestinal disorders (nausea, vomiting, abdominal pain, taste disturbances, dyspepsia or difficulty of digestion, diarrhoea, constipation, change of bowel habit), allergic reactions (such as skin rashes, itching), muscle spasms, feeling of tiredness, weakness, somnolence, ankle swelling.</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Uncommon (may affect up to 1 in 100 people):</p><p>Mood swings, anxiety, depression, sleep disturbances, trembling, hives, fainting, loss of pain sensation, irregular and/or rapid heartbeat, rhinitis (blocked up or runny nose), hair loss, purpura (red pinpoints on skin), skin discolouration, itchy skin, sweating, chest pain, joint or muscle pain, back pain, pain, feeling unwell (malaise), kidney problems, disorder in passing urine, increased need to urinate at night, increased number of times of passing urine, impotence (inability to obtain or maintain an erection), fever or high temperature, discomfort or enlargement of the breasts in men, weight increased or decreased, increase in some white blood cells, high potassium levels in the blood, hypoglycaemia (very low blood sugar level), low sodium levels in the blood that may lead to dehydration and low blood pressure, vasculitis (inflammation of blood vessels), photosensitivity reaction (change in skin appearance) after exposure to the sun or artificial UVA, blister clusters over the skin, swelling of hands or feet, blood creatinine increased and blood urea increase, fall, dry mouth.</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rare (may affect up to 1 in 1000 people):</p><p>Confusional state, changes in laboratory parameters: low chloride in the blood, low magnesium in the blood, increased level of liver enzymes, high level of serum bilirubin and psoriasis worsening, decrease or absence urine output, acute renal failure.<br /><br />Dark urine, feeling sick (nausea) or being sick (vomiting), muscle cramps, confusion and seizures. These may be symptoms of a condition called SIADH (inappropriate antidiuretic hormone secretion).</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Very rare (may affect up to 1 in 10,000 people):</p><p>Decreased numbers of white blood cells, decrease in the number of platelets (which causes easy bruising and nasal bleeding), anaemia (decrease in red blood cells), angina pectoris (pains to the chest, jaw and back , brought on by physical effort, and due to problems with the blood flow to the heart), eosinophilic pneumonia (a rare type of pneumonia), swelling of the gums, severe skin reactions including intense skin rash, reddening of the skin over your whole body, severe itching, blistering, peeling and swelling of the skin, erythema multiforme (a skin rash which often starts with red itchy patches on your face, arms or legs), bleeding, tender or enlarged gums, abnormal liver function, inflammation of the liver (hepatitis), severe kidney problems, yellowing of the skin (jaundice), abdominal bloating (gastritis), disorder of the nerves which can cause weakness, tingling or numbness, increased muscle tension, hyperglycaemia (very high blood sugar level), high level of calcium in the blood, stroke possibly secondary to excessive low blood pressure.</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Not known (frequency cannot be estimated from the available data):</p><p>Hepatic encephalopathy (disease of the brain caused by liver illness), abnormal ECG heart tracing, if you suffer from systemic lupus erythematosus (a type of collagen disease), this might get worse.</p><p>Short sightedness (myopia), vision blurred, decrease in vision or pain in your eyes due to high pressure (possible signs of fluid accumulation in the vascular layer of the eye (choroidal effusion) or acute angle-closure glaucoma).</p><p>Trembling, rigid posture, mask-like face, slow movements and a shuffling, unbalanced walk.</p><p>Discoloration, numbness and pain in fingers or toes (Raynaud&rsquo;s phenomenon).</p><p>&nbsp;</p><p>Changes in laboratory parameters (blood tests) can occur. Your doctor may need to give you blood tests to monitor your condition.</p><p><br />&nbsp;If you have these symptoms contact your doctor as soon as possible.</p><p>&nbsp;</p><p><strong>Reporting of side effects</strong></p><p>If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting. By reporting side effects you can help provide more information on the safety of this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>&nbsp;</p><p>Do not use this medicine after the expiry date which is stated on the carton and tablet container. The expiry date refers to the last day of that month.</p><p>&nbsp;</p><p>This medicinal product does not require any special storage conditions.</p><p>&nbsp;</p><p>For the container of 28 and 30 film-coated tablet, the in-use stability after first opening is 30 days.</p><p>For the container of 100 film-coated tablet, the in-use stability after first opening is 100 days.</p><p>&nbsp;</p><p>Do not throw away any medicine via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer used. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What Triplixam</strong> <strong>contains</strong></p><p><u>&nbsp;</u></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substances are perindopril arginine, indapamide and amlodipine</p><p><em>&nbsp;</em></p><p>One film-coated tablet of :</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Triplixam 5/1.25/5 mg contains 3.395 mg perindopril equivalent to 5mg perindopril arginine, 1.25 mg indapamide and 6.935mg amlodipine besilate &nbsp;equivalent to 5 mg of amlodipine.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Triplixam 5/1.25/10&nbsp; mg contains 3.395 mg perindopril equivalent to 5mg perindopril arginine, 1.25 mg indapamide and 13.870mg amlodipine besilate&nbsp; equivalent to 10 mg of amlodipine.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Triplixam 10 /2.5/5 mg contains 6.790 mg perindopril equivalent to 10 mg perindopril arginine, 2.5 mg indapamide and 6.935mg amlodipine besilate&nbsp; equivalent to 5 mg of amlodipine.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Triplixam 10 /2.5/10 mg contains 6.790 mg perindopril equivalent to 10 mg perindopril arginine, 2.5 mg indapamide and 13.870 mg amlodipine besilate&nbsp; equivalent to 10 mg of amlodipine.</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredients are:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tablet core: Calcium carbonate starch compound: Calcium carbonate 90 %<em>,</em> Pregelatinised maize starch 10%,<em> </em>cellulose microcrystalline (E460), croscarmellose sodium (E468), magnesium stearate (E572), colloidal anhydrous silica, pregelatinised starch.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tablet film-coating: Glycerol(E422), hypromellose 6mPa.s(E464), macrogol 6000, magnesium stearate(E572), titanium dioxide (E171).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                
Triplixam 5/1.25/5 mg are white, oblong, film-coated tablet, 9.75 mm long and 5.16 mm wide, engraved with   on one face and   on the other face.
Triplixam 5/1.25/10 mg are white, oblong, film-coated tablet, 10.7 mm Long and 5.66 mm wide, engraved with   on one face and   on the other face.
Triplixam 10/2.5/5 mg are white, oblong, film-coated tablet, 11.5 mm long and 6.09 mm wide, engraved with   on one face and   on the other face.
Triplixam 10/2.5/10 mg are white, oblong, film-coated tablet, 12.2 mm long and 6.46 mm, engraved with   on one face and   on the other face.

The tablets are available in box of 10, 28, 30, 60 (2 tablet containers of 30), 84 (3 tablet containers of 28), 90 (3 tablet containers of 30), 100 and 500 tablets (5 tablet containers of 100).

The desiccant is present in the stopper of the tablet containers.
	Not all pack sizes may be marketed.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&nbsp;</p><p>Les Laboratoires Servier</p><p>50, rue Carnot</p><p>92284 Suresnes cedex - France</p><p><strong>&nbsp;</strong></p><p><strong>Manufacturers:</strong></p><p>&nbsp;</p><p>Servier (Ireland) Industries Ltd</p><p>Gorey Road</p><p>Arklow - Co. Wicklow &ndash; Ireland</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Saudi Arabia </strong></p><p>Servier Saudi Arabia Scientific Office</p><p>3533 Al Hawiy - Hitteen Dist.</p><p>1st floor - Office #101</p><p>Kingdom of Saudi Arabia</p><p>Tel.: +966 011 252 2330</p><p>E-mail: regulatory.sa1@servier.com</p></td><td style="vertical-align:top"><p><strong>Gulf Countries </strong></p><p>Les Laboratoires Servier Scientific Office</p><p>P.O. Box 1586, Level 15, Arenco Tower, Dubai Media city, Sheikh Zayed Road,</p><p>Dubai, UAE</p><p>Tel: +971 4 3329903</p><p>E-mail: magdy.abdou@servier.com</p></td></tr></tbody></table><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                	This leaflet was last revised in 09.2022
	
To report any side effect(s): 

•	Saudi Arabia:

- National Pharmacovigilance Center (NPC)
- SFDA call Center 19999
- E-mail: npc.drug@sfda.gov.sa
- Website: https://ade.sfda.gov.sa/

•	Other GCC states:

- Please contact the relevant competent authority.
	

Council of Arab Health Ministers: 


This is a Medicament

Medicament is a product which affects your health and its consumption contrary to instructions is dangerous for you.
- Follow the doctor's prescription, the method of use and the instruction of the pharmacist who sold the medicament.
- The doctor and the pharmacist are the experts in medicines, their benefits and risks.
- Do not by yourselves interrupt the period of treatment prescribed for you.
- Do not repeat the same prescription without consulting your doctor.
	- Keep all medicaments out of reach of children
Council of Arab Health Ministers
Union of Arab Pharmacists


	This patient information leaflet is approved by the Saudi Food and Drug Authority
	



            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">الفئة الصيدلانية العلاجية: مثبطات خميرة تحويل الأنجيوتنسين، مزيج: مثبط خميرة تحويل الأنجيوتنسين، حاصر قنوات الكالسيوم ومدّر للبول - الرمز التشريجي العلاجي: C09BX01.</p><p dir="RTL">يتألف تريبليكسام من مزيج ثلاثة مواد فعّالة: البيريندوبريل والانداباميد والأملوديبين. وهو دواء خافض لضغط الدم يستعمل في علاج الضغط الشرياني المرتفع (ارتفاع الضغط الشرياني).&nbsp;</p><p dir="RTL">يمكن للمرضى الذين يتناولون بالفعل جرعة ثابتة من مزيج البيريندوبريل والانداباميد مع الأملوديبين كقرص منفصل، أن يتلقوا بدلا من ذلك قرصا واحدا من تريبليكسام يحتوي على العناصر الفعّالة الثلاثة بنفس القوّة.</p><p dir="RTL">تعمل كل مادة فعالة على خفض ضغط الدم، وهي تعمل معا للتحكّم بضغط دمك:&nbsp;&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ينتمي البيريندوبريل إلى الأدوية المعروفة باسم مثبطات خميرة تحويل الأنجيوتنسين (ACE inhibitor)، وهو يقوم بتوسيع الأوعية الدموية مسهلاً بذلك عمل القلب بضخ الدم عبرها.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإنداباميد هو مدّر للبول (ينتمي إلى مجموعة من الأدوية تدعى مشتقات السلفوناميد التي تحتوي على حلقة إندول). تسبب معظم المدرّات زيادة كمية البول الذي تنتجه الكليتان، ولكن الإنداباميد يختلف عن المدرّات الأخرى بأنه يزيد كمية البول بشكل ضئيل.&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأملوديبين حاصر لقنوات الكالسيوم (ينتمي إلى المجموعة العلاجية التي يطلق عليها اسم ديهايدروبيريدين). وهو ذو تأثير مرخي للأوعية الدموية، مما يسمح بانتقال الدم فيها بسهولة أكبر.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">لا تتناول تريبليكسام حبّات ملبّسة:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصابا بالحساسية تجاه مادة البيريندوبريل، أو تجاه صنف آخر من مثبطات الخميرة المحولة للأنجيوتنسين، أو تجاه الإنداباميد أو غيره من السلفوناميدات، أو تجاه الأملوديبين أو غيره من أدوية مجموعة الديهايدروبيريدين، أو أي تجاه مادة أخرى تدخل في تركيب هذا الدواء المذكورة في القسم ٦،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إن عانيت من أعراض مثل الصفير أثناء التنفس، أو تورم الوجه أو اللسان، أو من حكّة شديدة، أو حالات طفح جلدي شديد أثناء علاج سابق بواسطة مثبطات الخميرة المحولة للأنجيوتنسين، أو إن سبق وظهرت هذه الأعراض في أي ظروف أخرى لك أو لأحد أفراد أسرتك (وهي حالة تُدعى الوذمة الوعائيّة)،&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من مرض كبدي شديد أو من الإعتلال الدماغي الكبدي (اضطراب عصبي يحدث بسبب مرض الكبد)،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان يشتبه بإصابتك بفشل قلبي غير معاوض وغير معالج (احتباس شديد للماء، صعوبة في التنفس)&nbsp;&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من تضيّق الصمام الأورطي (تضيق أورطي) أو من صدمة قلبية المنشأ (حالة لا يتمكن فيها القلب من ضخّ كمية كافية من الدم إلى الجسم)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من فشل قلبي بعد نوبة قلبية&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان ضغط دمك منخفضا بشدة (انخفاض ضغط الدم)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كانت معدّلات البوتاسيوم في دمك منخفضة&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من مشاكل كلوية شديدة مع نقص تدفق الدم إلى الكليتين (تضيّق الشريان الكلوي)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تخضع للديلزة أو أي نوع آخر من عمليات تنقية الدم. قد يكون تريبليكسام غير مناسب لك اعتمادا على الآلة المستخدمة،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من مشاكل كلوية متوسطة الشدة (بالنسبة لجرعات تريبليكسام التي تحتوي على ١٠ ملغ/٢٫٥ ملغ/٥ ملغ والتي تحتوي على ١٠ ملغ/٢٫٥ ملغ/١٠ ملغ)&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في حال كنتِ حاملًا منذ أكثر من ثلاثة أشهر (كما يستحسن تجنّب تناول تريبليكسام في المراحل المبكرة من الحمل &ndash; راجعي قسم الحمل)،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إو إذا كنت مصابا بالسكري أو كىت تعاني من قصور كلوي وتتلقى علاجا بدواء يحتوي على أليسكيرين لخفض الضعط الشرياني،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت قد تلقيت أو تتلقى حاليا علاجا بـ ساكوبتريل/فالسارتان، وهو دواء لعلاج قصور القلب نظرا لازدياد إمكانية حدوث الوذمة الوعائية (تورم سريع تحت الجلد في منطقة كالبلعوم)، (راجع قسمي &quot;تحذيرات واحتياطات&quot; و &quot;الأدوية الأخرى و تريبليكسام&quot;).</p><p dir="RTL">تحذيرات واحتياطات</p><p dir="RTL">الرجاء التحدث إلى طبيبك أو الصيدلاني أو الممرض/الممرضة قبل تناول تريبليكسام حبّات ملبّسة:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إن كنت تعاني من اعتلال مضخّم في عضلة القلب (مرض في عضلة القلب)، أو تضيّق في الشريان الكلوي (أي تضيّق في الشريان الذي يمدّ الكلية بالدم)،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إن كنت تشكو من فشل قلبي أو أي مشكلة قلبية أخرى،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إن كنت تعاني من ارتفاع شديد في ضغط الدم (نوبة فرط الضغط)،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إن كنت تشكو من مرض في الكبد،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إن كنت تشكو من داء كولاجيني (مرض في الجلد)، مثل الذئبة الحمامية الجهازية أوالتصلّب الجلدي،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إن كنت مصابا بالتصلب العصيدي (تصلب الشرايين)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إن كنت بحاجة لإجراء فحص للغدّة الدريقية،&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إن كنت تعاني من النقرس،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إن كنت مصاباً بداء السكري،&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إن كنت خاضعاً لحمية قليلة الملح (منخفضة الصوديوم)، أوتستعمل بدائل الملح التي تحتوي على البوتاسيوم (توازن معدل البوتاسيوم في الدم بشكل جيد أمر أساسي)،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إن كنت تتناول الليثيوم أو المدرّات الموفّرة للبوتاسيوم (سبيرونولاكتون، تريامتيرين) لأنه يجب تجنّب استعمال هذه الأدوية مع تريبليكسام (راجع قسم &quot;الأدوية الأخرى وتريبليكسام حبّات ملبّسة&quot;)،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إن كنت مسنّا وكانت جرعتك بحاجة لزيادتها،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إن كنت مصابا بتفاعلات تحسسية ضوئية،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إن كنت تنتمي إلى العرق الأسود فقد تكون أكثر عرضة للإصابة بالوذمة الوعائية (تورّم الوجه والشفتين والفم واللسان أو البلعوم مما قد يسبب صعوبة في البلع أو التنفس) وقد تكون فاعلية الدواء في خفض الضغط الشرياني لديك أقل،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إن كنت مريضا تخضع للتحال الدموي باستعمال الأغشية العالية النفوذية،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إن كنت تشكو من مشاكل كلوية أو تخضع للديلزة،&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تشكو من تراجع الرؤية أو من ألم في العينين. قد تكون هذه أعراض تراكم السوائل في الطبقة الوعائية للعين (انصباب مشيمي)، أو لارتفاع الضغط في العين، ومن الممكن أن تحدث في غضون ساعات أو أسابيع من تناول تريبليكسام حبّات ملبّسة، وقد تؤدي إلى فقدان البصر إذا تركت دون علاج. إذا كنت مصابا بالحساسية تجاه البنسلين أو السلفاميدات، فربما تكون أكثر عرضة للإصابة به،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من أي مشاكل عضلية، ومن ضمنها الألم، أو المضض، أو الضعف أو التشنجات،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كانت لديك معدلات مرتفعة بشكل غير طبيعي من هرمون الألدوستيرون في الدم (الأدوستيرونيّة الأوليّة)،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إن كان معدل الحموض مرتفعا جدا في دمك، مما قد يسبب ارتفاع معدّل التنفس،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إن كنت تشكو من قصور في الدوران الدماغي (انخفاض ضغط الدم في الدماغ)،&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا أُصبت بتورم الوجه والشفتين والفم واللسان أو البلعوم الذي قد يسبب صعوبة في البلع أو التنفس (وذمة وعائية)، والذي قد يحدث في أي وقت أثناء العلاج، توقف فورا عن تناول العلاج واتصل مباشرة بطبيبك،&nbsp;&nbsp;&nbsp;&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتناول ايا من الأدوية التالية، فإن أمكانية الإصابة بالوذمة الوعائية ترتفع:</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; راسيكادوتريل (الذي يستعمل لعلاج الإسهال)،</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيروليموس، إيفيروليموس، تمسيروليموس والأدوية الأخري التي تنتمي إلى مجموعة الأدوية التي تدعى مثبطات الهدف الميكانيكي لرابامايسين mTOR inhibitors (التي تستعمل لتفادي رفض الأعضاء المزروعة ولعلاج السرطان)،&nbsp;</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ساكوبتريل (الذي يتوفر بجرعة ثابتة بالاشتراك مع فالسارتان)، والذي يستعمل لعلاج قصور القلب المزمن،</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ليناغلبتين، ساكساغلبتين، سيتاغلبتين، فيلداغلبتين، وكافة الأدوية الأخرى التي تنتمي إلى مجموعة غلبتين (التي تستعمل لعلاج السكري).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتناول أياً من الأدوية التالية التي تستعمل لعلاج ضغط الدم المرتفع:&nbsp;&nbsp;&nbsp;</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أحد حاصرات مستقبلات الأنجيوتنسين &Iota;&Iota; (التي تعرف أيضا باسم مجموعة السارتان &ndash; مثل فالسارتان، تلميسارتان، إربيسارتان)، وخاصة إذا كنت تشكو من اضطرابات كلوية ذات صلة بالسكري،</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أليسكيرين.</p><p dir="RTL">قد يقوم طبيبك بالتأكد من وظيفتك الكلوية، ضغط الدم، وكمية الشوارد الكهربائية (مثل البوتاسيوم) في دمك على فترات منتظمة.</p><p dir="RTL">راجع قسم &quot;الأدوية الأخرى وتريبليكسام حبّات ملبّسة&quot;،</p><p dir="RTL">قد يطلب طبيبك إجراء فحوص مخبرية للدم لمراقبة معدلات الصوديوم أو البوتاسيوم المنخفضة، أو معدلات الكالسيوم المرتفعة.</p><p dir="RTL">يجب أن تبلغي طبيبك إذا كنت تعتقدين بأنك حامل (أو أنك قد تصبحين) حاملًا. يوصى بعدم تناول تريبليكسام في الفترات المبكرة من&nbsp; الحمل، ولا يجوز تناوله على الإطلاق بعد الشهر الثالث للحمل، لأنه قد يسبب أذى شديدا لطفلك إذا استعمل في هذه المرحلة (راجعي &quot;الحمل والإرضاع&quot;).</p><p dir="RTL">أثناء العلاج&nbsp; بواسطة تريبليكسام، عليك بأن تعلم طبيبك أو العاملين في مجال الطب في الحالات التالية:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت ستخضع للتخدير الطبي، و/ أو عملية جراحية،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا عانيت مؤخراً من الإسهال أو القيء، أو كنت تعاني من الجفاف،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت سوف تخضع للتحال أو لإجراء التصفية الآلية للكوليستيرول المنخفض الكثافة LDL في الدم (أي عمليّة آليّة لسحب الكوليسترول من الدم)،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت ستخضع لعلاج لإزالة التحسس لتخفيف تأثير الحساسية تجاه لسعات النحل أو الدبابير،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت ستخضع لإجراء فحص طبي يتطلب حقن عامل ظليل يودي (مادة تجعل أعضاء الجسم مثل الكلية والمعدة مرئية على الأشعة السينية).</p><p dir="RTL">يُلفت انتباه الرياضيين إلى أن هذا الدواء يحتوي على مادة فعّالة قد تعطي نتائج إيجابيّةً في اختبار تناول المنشطات.&nbsp;&nbsp;&nbsp;&nbsp;</p><p dir="RTL">الأطفال والمراهقون</p><p dir="RTL">يجب عدم إعطاء تريبليكسام للأطفال والمراهقين.</p><p dir="RTL">الأدوية الأخرى وتريبليكسام حبّات ملبّسة</p><p dir="RTL">الرجاء إعلام طبيبك أو الصيدلاني إذا كنت تتناول حالياً أو تناولت مؤخّراً أو قد تتناول أي أدوية أخرى.</p><p dir="RTL">لا تتناول أليسكيرين (دواء يستعمل لعلاج ارتفاع الضغط) إذا كنت مصابا بالسكري أو تعاني من مشاكل في الكلية.</p><p dir="RTL">تجنّب تناول تريبليكسام مع:&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الليثيوم (المُستعمل في علاج الاضطرابات الذهنية مثل الهَوَس أو المرض الهوسي الاكتئابي والاكتئاب المتكرر)،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية الموفّرة للبوتاسيوم ( مثل: أميلوريد، تريامتيرين)، أو مكمّلات البوتاسيوم، أو بدائل الملح المحتوية على البوتاسيوم، الأدوية الأخرى التي يمكنها زيادة معدّل البوتاسيوم في جسمك (مثل الهيبارين الذي يستعمل لتمييع الدم ومنع التخثر؛ وترايميثوبريم وكوتريموكسازول والذي يعرف أيضا باسم ترايميثوبريم/سلفاميثوكسازول لعلاج حالات العدوى البكترية)،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دانترولين (عن طريق التسريب) الذي يستعمل أيضا لعلاج فرط الحرارة الخبيث أثناء التخدير (تشمل الأعراض ارتفاع الحرارة الشديد وتيبّس العضلات)،&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إسترامُستين (الذي يستعمل لعلاج السرطان)،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية التي كثيرا ما تستعمل لعلاج الإسهال (راسيكادوتريل) أو لتفادي رفض الأعضاء المزروعة (سيروليموس، إيفيروليموس، تيمسيروليموس وأدوية أخرى من الأدوية التي تدعى مثبطات m-Tor). راجع قسم &quot;تحذيرات واحتياطات&quot;،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ساكوبتريل/فالسارتان (الذي يستعمل لعلاج قصور القلب المزمن). راجع قسم &quot;لا تتناول تريبليكسام&quot; و&quot;تحذيرات واحتياطات&quot;.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية الأخرى المستعملة لعلاج ارتفاع الضغط الشرياني: مثبطات خميرة تحويل الأنجيوتنسين وحاصرات مستقبلات الأنجيوتنسين.&nbsp;&nbsp;&nbsp;&nbsp;</p><p dir="RTL">وقد يتأثر العلاج باستعمال تريبليكسام بالأدوية الأخرى. قد يحتاج طبيبك إلى تعديل جرعتك و/أو اتخاذ احتياطات أخرى. يجب إبلاغ طبيبك إذا كنت تتناول حاليًا أياً من الأدوية التالية، لاتخاذ الاحتياطات الخاصة:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية الأخرى لعلاج ارتفاع ضغط الدم، بما فيها حاصرات مستقبلات الأنجيوتنسين &Iota;&Iota; أو أليسكيرين (راجع أيضاً المعلومات الواردة في قسم &quot;لا تتناول تريبليكسام أقراص ملبّسة&quot; وقسم &quot;تحذيرات واحتياطات&quot;)، أو المدرات (الأدوية التي تزيد من كمية البول الذي تنتجه الكليتان)،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية المدرّة الموفّرة للبوتاسيوم المستعملة في علاج قصور القلب: إيبليرينون وسبيرونولاكتون بجرعات تتراوح بين ١٢٫٥ ملغ و٥٠ ملغ يوميا،&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية التخدير،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; العوامل الظليلة التي تحتوي على اليود،&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ببريديل (المُستخدم لعلاج الذبحة الصدرية)،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ميتادون (الذي يستعمل في علاج الإدمان).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية المستعملة لعلاج عدم انتظام ضربات القلب (مثل: دوفيتيليد، إيبوتيليد، بريتيليوم، سيزابريد، ديفيمانيل، بروكايين آميد، كينيدين، هيدروكينيدين، ديزوبيراميد، أميودارون، سوتالول)،&nbsp;&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فيراباميل، ديلتيازم (أدوية للقلب)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الديجوكسين أو الغليكوزيدات القلبية الأخرى (المستعملة لعلاج أمراض القلب)،&nbsp;&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مضادات حيويّة لمعالجة حالات العدوى البكتيرية (مثل: ريفامبيسين، إريثرومايسين عن طريق الحقن، كلاريثرومايسين، سبارفلوكساسين، موكسيفلوكساسين)،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;الأدوية المضادة للفطريات (مثل: إتراكونازول، كيتوكونازول، أمفوتريسين ب عن طريق الحقن)،&nbsp;&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; آلوبورينول (لعلاج النقرس)،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مضادات الهستامين التي تستعمل لعلاج التفاعلات التحسسية، مثل حمى القشّ (مثل: ميزولاستين، تيرفينادين، أستيميزول)،&nbsp;&nbsp;&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الكورتيكوستيرويدات التي تستعمل لعلاج اضطرابات مختلفة بما فيها الربو الشديد والتهاب المفاصل المتعددة الروماتويدي، و&nbsp; مضادات الالتهاب غير الستيرويديّة (مثل الإيبوبروفين) أو الجرعات المرتفعة من حمض الساليسيلك (المادة التي توجد في العديد من الأدوية التي تستعمل لتخفيف الألم وخفض الحرارة، بالإضافة إلى منع تشكل الخثرات(،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كابتات المناعة (الأدوية التي تستعمل للسيطرة على التفاعل المناعي في جسمك لعلاج أمراض المناعة الذاتيّة أو بعد عمليّة غرس الأعضاء (مثل سيكلوسبورين، تاكروليموس)،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تيتراكوزاكتيد (لعلاج داء كرون)،&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أملاح الذهب، وخاصة التي تعطى داخل الوريد (والتي تستعمل لعلاج أعراض التهاب المفاصل الروماتويدي)،&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; هالوفانترين (مضاد للطفيليّات لعلاج بعض أنواع الملاريا)،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; باكلوفين المستعمل في علاج التيبس العضلي في أمراض مثل التصلب المتعدد،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية المستعملة في علاج داء السكّري مثل الأنسولين أو المتفورمين،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الكلسيوم بما في ذلك مكمّلات الكلسيوم،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المسهّلات المنبّهة (مثل سينّا)،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية المستعملة في علاج السرطان،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فنكامين (الذي يستعمل للعلاج العرضي لاضطراب الإدراك لدى المسنين بما فيها فقد الذاكرة)،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية المستعملة في علاج الاضطرابات الذهنية مثل الاكتئاب أو القلق أو الفصام إلخ (منها مضادات الاكتئاب ثلاثيّة الحلقات ومضادات الذهان، مضادات الاكتئاب من نوع الإيميبرامين، مضادات الذهان (مثل أميسولبريد، سولبيريد، سولتوبريد، تيلبريد، هالوبيريدول، دروبيريدول)،&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بنتاميدين (لعلاج ذات الرئة)،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ريتونافير، إندينافير، نلفينافير (وتدعى مثبطات البروتياز وتستعمل لعلاج عدوى فيروس نقص المناعة البشري)،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; هيبيريكوم بيرفوراتوم (عشبة سانت جون)&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ترايميثوبريم (لعلاج حالات العدوى)،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية المستعملة في علاج هبوط الضغط الشرياني، أو في علاج الصدمة أو في علاج الربو (منها إفيدرين أو نورأدرينالين أو أدرينالين)،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; النتروغليسيرين والنترات الأخرى، أو الموسعات الوعائية الأخرى التي قد تنقص ضغط الدم أكثر.&nbsp;&nbsp;&nbsp;</p><p dir="RTL">تريبليكسام حبّات ملبّسة مع الطعام والشراب</p><p dir="RTL">يجب الامتناع عن تناول الجريب فروت أو عصير الجريب فروت من قبل الأفراد الذين يتناولون تريبليكسام. وهذا يرجع إلى أن الجريب فروت وعصيره قد يرفعان المعدّلات الدموية لمادة الأملوديبين الفعالة، مما قد يسبب زيادة غير متوقعة في تأثيرات تريبليكسام الخافضة للضغط.&nbsp;&nbsp;&nbsp;</p><p dir="RTL">الحمل والإرضاع</p><p dir="RTL">إذا كنت حاملا أو مرضعا، أو تعتقدين بأنك حامل أو تخططين للإنجاب، عليكِ باستشارة طبيبك أو الصيدلاني قبل المباشرة بأخذ هذا الدواء.</p><p dir="RTL">الحمل</p><p dir="RTL">يجب أن تبلغي طبيبك إذا كنت تعتقدين بأنك حامل (أو أنك قد تصبحين حاملًا).</p><p dir="RTL">سينصحك طبيبك في الأحوال الطبيعية بالتوقف عن تناول تريبليكسام قبل حدوث الحمل أو بمجرد أن تعلمي بحدوثه. وسوف ينصحك بتناول دواء آخر بدلا من تريبليكسام. يوصى بعدم تناول تريبليكسام في المراحل المبكرة من الحمل، ولا يجوز أخذه على الإطلاق بعد الشهر الثالث للحمل، فقد يؤدي هذا إلى إصابات خطيرة لطفلك، إذا استعمل بعد الشهر الثالث من الحمل.</p><p dir="RTL">الإرضاع &nbsp;</p><p dir="RTL">أبلغي طبيبك إن كنت مرضعا أو إن كنت سوف تباشرين بالإرضاع. لا يُنصح بأخذ تريبليكسام لدى المرأة المرضع، فإن كنت ترغبين بالإرضاع، بإمكان طبيبك أن يختار لك دواء آخر، وخاصة إن كان الطفل حديث الولادة أو خديجا (مولودا قبل الأوان).&nbsp;</p><p dir="RTL">قيادة السيارات وتشغيل الآليات</p><p dir="RTL">قد يؤثّر تريبليكسام على قدرتك على القيادة أو استعمال الآليات. إذا سببت لك الأقراص الشعور بالغثيان أو الدوخة أو التعب أو&nbsp; سببت لك الصداع، فيجب أن تمتنع عن قيادة السيارات أو تشغيل الآليات ويجب أن تتصل بطبيبك على الفور.&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p dir="RTL">يحتوي تريبليكسام حبّات ملبّسة على الصوديوم</p><p dir="RTL">يحتوي تريبليكسام على أقل من ١ ممول (٢٣ ملغ) من الصوديوم في الحبة الواحدة مما يعني أنه&nbsp; بالأساس &quot;خال من الصوديوم&quot;.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">عليك دائماً الالتزام بتناول هذا الدواء بالطريقة التي وصفها لك طبيبك أو الصيدلاني. فإن لم تكن متأكدا، عليك باستشارة طبيبك أو الصيدلاني.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">الجرعة</p><p dir="RTL">يجب ابتلاع القرص مع كأس من الماء، ويفضّل تناوله في الصباح قبل وجبة الإفطار. إن طبيبك هو الذي يحدّد مقدار الجرعة المناسبة لك. يبلغ مقدار الجرعة الموصى بها قرص واحد يوميا.&nbsp;</p><p dir="RTL">إذا تناولت جرعة أكبر مما ينبغي من تريبليكسام حبّات ملبّسة &nbsp;</p><p dir="RTL">اتصل فورًا بطبيبك أو بالصيدلاني.&nbsp;&nbsp;</p><p dir="RTL">&nbsp;إذا تناولت عددا كبيرا من أقراص تريبليكسام، فقد تسبب انخفاض ضغط الدم إلى درجة خطيرة، وقد يترافق أحيانا&nbsp; بالغثيان والإقياء والتشنجات والدوخة والنعاس، وحالة الارتباك، وقلة البول (إخراج كميات أقل من المعتاد)، وانقطاع البول (عدم إنتاج البول). قد تشعر بخفّة الرأس أو الإغماء أو الضعف. وإذا انخفض الضغط بشدة فمن الممكن أن تحدث صدمة. قد يصبح جلدك باردا ورطبا وقد تغيب عن الوعي.&nbsp;</p><p dir="RTL">قد يتراكم السائل الزائد في رئتيك (الوذمة الرئوية) مما يسبب ضيقًا في التنفس وقد يتطور الأمر خلال ٢٤ إلى ٤٨ ساعة بعد تناوله.</p><p dir="RTL">إذا تناولت عددا كبيرا من أقراص تريبليكسام، فاتصل على الفور بالطبيب.&nbsp;&nbsp;</p><p dir="RTL">إذا نسيت تناول تريبليكسام حبّات ملبّسة&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p dir="RTL">من المهم أن تتناول دواءك كل يوم لأن العلاج المنتظم أكثر فعالية. ولكن إذا نسيت تناول إحدى جرعات تريبليكسام، فعليك أن تتناول جرعتك التالية في وقتها المعتاد. لا تتناول جرعة مضاعفة للتعويض عن الجرعة التي نسيت تناولها.&nbsp;</p><p dir="RTL">إذا توقفت عن تناول تريبليكسام حبّات ملبّسة&nbsp;</p><p dir="RTL">نظرا لأن علاج الضغط الشرياني المرتفع يستمر طيلة الحياة عادة، لذا يجب أن تستشير طبيبك قبل التوقف عن تناول هذا الدواء.&nbsp;</p><p dir="RTL">إذا كانت لديك أي أسئلة إضافية تتعلق باستعمال هذا الدواء، فالرجاء أن تسأل طبيبك أو الصيدلاني أو الممرض/الممرضة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">كما هي الحال مع كافة الأدوية، من الممكن أن يسبب هذا الدواء آثارا جانبية، رغم أنها لا تصيب كافة الأشخاص.</p><p dir="RTL">إن لاحظت حدوث أيّ من الآثار الجانبيّة التالية، عليك التوقف عن أخذ هذا الدواء والاتصال بطبيب فوراً:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أزيز مفاجئ، ألم في الصدر، ضيق النفس أو صعوبة التنفس (حالات غير شائعة)، (&ge; ١/١٠٠٠، &lt;١٠٠)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورّم الجفنين أو الوجه أو الشفتين (حالات غير شائعة) (&ge; ١/١٠٠٠، &lt;١٠٠)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورّم الفم، اللسان والحلق مما يؤدي إلى صعوبة شديدة في التنفس (حالات غير شائعة) (&ge; ١/١٠٠٠، &lt;١٠٠)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات جلدية شديدة، تتضمن طفحا جلديا شديدا، شرى، احمرار الجلد في كامل الجسم، حكة شديدة، نفاطات، تقشر الجلد وتورمه، التهابات في الطبقة المخاطية (متلازمة ستيفنس جونسن) أو تفاعلات تحسسية أخرى (حالات نادرة جدا) (&lt; ١ / ١٠٠٠٠)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دوخة شديدة أو إغماء (حالات شائعة) (&ge; ١/١٠٠، &lt;١٠)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نوبة قلبية (حالات نادرة جدا)&nbsp; (&lt; ١/١٠٠٠٠)، ضربات قلب سريعة بشكل غير اعتيادي أوغير طبيعية (معدّل الحدوث غير معروف)، أو مهددة للحياة (معدّل الحدوث غير معروف)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب البنكرياس الذي يمكن أن يسبب ألما شديدا في البطن والظهر يرافقه انزعاج شديد&nbsp; (حالات نادرة جدا) (&lt; ١/١٠٠٠٠)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضعف، تشنجات، مضض العضلات أو ألمها، وبشكل خاص، إذا شعرت في نفس الوقت بتوعك أو ارتفاع في درجة الحرارة، فقد يكون ذلك بسبب التدرّك العضلي غير الطبيعي (معدّل حدوثها غير معروف)</p><p dir="RTL">من الممكن أن تشمل الآثار الجانبية ما يلي وذلك حسب الترتيب التنازلي لمعدل حدوثها:</p><p dir="RTL">شائعة جدا (قد تحدث لدى أكثر من ١ من ١٠ مستخدمين):</p><p dir="RTL">وذمة (احتباس الماء).</p><p dir="RTL">شائعة (&ge; ١/١٠٠، &lt; ١/١٠):</p><p dir="RTL">انخفاض معدل البوتاسيوم في الدم، صداع، دوخة، خفقان (الشعور بضربات القلب)، تبيّغ، الإحساس بالدوار، الإحساس بوخز الإبر&nbsp; والدبابيس، ، اضطرابات الرؤية، الرؤية المزدوجة، الطنين (الإحساس بالضجيج في الأذن)، شعور بخفة الرأس بسبب انخفاض الضغط الشرياني، سعال، ضيق في التنفس، اضطرابات معدية معوية (غثيان، قيء، ألم البطن، اضطراب في التذوّق، عسر هضم أو صعوبة الهضم، إسهال، إمساك، اضطراب الجركة المعوية)، تفاعلات تحسسيّة (مثل حالات الطفح الجلدي، أو الحكّة)، تشنجات عضلية، الإحساس بالتعب، ضعف، نعاس، تورّم الكاحلين.&nbsp;</p><p dir="RTL">غير شائعة (&ge; ١/١٠٠٠، &lt; ١/١٠٠):</p><p dir="RTL">تبدلات مزاجية، قلق، اكتئاب، اضطرابات في النوم، رجفان، شرى، إغماء، غياب الشعور بالألم، ضربات قلب غير منتطمة و / أو سريعة، التهاب الأنف (احتقان الأنف أو سيلان الأنف)، سقوط الشعر، فرفرية (ظهور نقاط حمراء على الجلد)، تبدّل لون الجلد، حكة جلدية، تعرّق، ألم في الصدر، ألم في المفاصل أو العضلات، ألم في الظهر، ألم، الشعور بالإعياء (توعّك)، مشاكل كلوية، صعوبة التبول، ازدياد الحاجة للتبول ليلا، ازدياد عدد مرات التبول، عنّة (عدم القدرة على الانتصاب أو المحافظة عليه)، حمى أو ارتفاع الحرارة، انزعاج أو تضخم الثدي عند الرجال، زيادة الوزن أو نقصانه، ارتفاع عدد بعض أنواع الكريات البيضاء، ارتفاع معدّل البوتاسيوم في الدم، هبوط معدل السكر في الدم (انخفاض شديد في معدّل سكر الدم)، انخفاض معدّل الصوديوم في الدم مما قد يسبب جفاف وانخفاض الضغط الشرياني ، التهاب الأوعية الدموية، تفاعلات تحسسية ضوئية (تغير مظهر الجلد) بعد التعرض للشمس أو للأشعة فوق البنفسجية، تشكل تجمعات نفاطية على الجلد، تورّم اليدين أو القدمين، وارتفاع معدّل الكرياتينين واليوريا في الدم ، السقوط، جفاف الفم.&nbsp;&nbsp;&nbsp;</p><p dir="RTL">نادرة (&ge; ١/١٠٠٠٠، &lt; ١/١٠٠٠):</p><p dir="RTL">ارتباك، تغير في المعايير المخبرية: انخفاض معدل الكلور في الدم، انخفاض معدل المغنيزيوم في الدم، ارتفاع معدّل الخمائر الكبدية، ارتفاع معدّل بيليروبين المصل وتفاقم حالة الصدفية، تناقص معدل إنتاج البول أو انعدامه، قصور كلوي حادّ.</p><p dir="RTL">&nbsp;بول مركّز، الغثيان أو التقيؤ، تشنج عضلي، ارتباك ونوبات. قد تكون هذه الأعراض ناجمة عن حالة الإفراز غير المناسب من</p><p dir="RTL">الهرمون المضادّ للإدرار.</p><p dir="RTL"><em>&nbsp;</em></p><p dir="RTL">نادرة جدا (&lt; ١/١٠٠٠٠):</p><p dir="RTL">انخفاض عدد الكريات البيضاء، انخفاض عدد الصفيحات (مما يؤدي إلى سهولة التكدّم ونزف الأنف)، فقر الدم (أي قلّة عدد الكريات الحمر)، ذبحة صدريّة (ألم في الصدر والفك والظهر، يحدث بسبب الجهد الجسدي، وبسبب مشاكل في تدفق الدم إلى القلب)، ذات الرئة اليوزينية (نوع نادر من ذات الرئة)، تورم اللثة، تفاعلات جلدية شديدة كالاندفاعات الجلدية الكثيفة، احمرار الجلد في جميع أنحاء الجسم، حكة شديدة، تشكل نفاطات، تقشر الجلد وتورمه، الحمامى المتعددة الأشكال (اندفاع جلدي كثيرا ما يبدأ بظهور بقع حمراء حاكة على الوجه، والذراعين أوالساقين)، لثة نازفة أو مؤلمة أو متورمة، اضطراب الوظيفة الكبدية، التهاب الكبد، مشاكل كلوية شديدة، اصفرار الجلد (اليرقان)، انتفاخ البطن (التهاب المعدة)، اضطرابات في الأعصاب مما قد يسبب الضعف أو الشعور بالوخز أو الخدر، ازدياد التوتر العضلي، ارتفاع معدّل السكر في الدم، ارتفاع معدل الكلسيوم في الدم، حادث وعائي دماغي قد يكون تاليا للهبوط الشديد في ضغط الدم.&nbsp;</p><p dir="RTL">الآثار الجانبية ذات المعدّل غير المعروف (لا يمكن تقدير معدّل حدوثها بالاستناد إلى البيانات المتوفرة في الوقت الحاضر):&nbsp;</p><p dir="RTL">اعتلال الدماغ الكبدي (اضطرابات عصبية بسبب مرض الكبد)، مخطط غير طبيعي لكهربية القلب، ازدياد شدة الذئبة الحمامية الجهازية (أحد أمراض الكولاجين).&nbsp;&nbsp;</p><p dir="RTL">تراجع الرؤية أو ألم العين بسبب الضغط المرتفع (علامات محتملة لتراكم السوائل في الطبقة الوعائية للعين (الانصباب المشيمي)، أو الغلوكوما (الزرق) الحاد مغلق الزاوية)،</p><p dir="RTL">رجفان، جمود الوضعية، وجه جامد عديم التعبير، حركات بطيئة وارتباك المشية وعدم اتزانها.</p><p dir="RTL">تبقّع، خدر وألم في أصابع اليدين أو القدمين (متلازمة رينو).</p><p dir="RTL">من الممكن أن يحدث تغير في المعايير المخبرية (فحوص الدم). وقد يطلب طبيبك إجراء فحوص الدم لمراقبة حالتك.</p><p dir="RTL">إذا أصبت بهذه الأعراض، فاتصل بطبيبك على الفور.&nbsp;&nbsp;&nbsp;&nbsp;</p><p dir="RTL">الإبلاغ عن الآثار الجانبية</p><p dir="RTL">إذا أصبت بأي آثار جانبية، تحدّث إلى طبيبك، أو الصيدلاني. هذا يشمل أي آثار جانبية ممكنة حتى ولو لم يرد ذكرها في هذه النشرة. كما يمكنك الإبلاغ عن الآثار الجانبية مباشرة عن طريق النظام الوطني للإبلاغ.</p><p dir="RTL">عند إبلاغك عن التأثیرات الجانبیة، فأنت تساھم في تقدیم مزید من المعلومات عن سلامة ھذا الدواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احتفظ بهذا الدواء بعيدًا عن مرأى عيون الأطفال ومتناول أيديهم.</p><p dir="RTL">لا تستعمل هذا الدواء بعد انقضاء تاريخ الصلاحية المذكور على العلبة الخارجية وعلى حاوي الأقراص المذكور بعد EXP.&nbsp;</p><p dir="RTL">تاريخ انتهاء الصلاحية هو آخر يوم من الشهر المُشار إليه.</p><p dir="RTL">يستمر الثبات بعد فتح حاويات الأقراص سعة ٢٨ و٣٠ حبة ملبسة لمدة ٣٠ يوما.</p><p dir="RTL">يستمر الثبات بعد فتح حاويات الأقراص سعة ١٠٠ حبة ملبسة لمدة ١٠٠ يوم.</p><p dir="RTL">لا توجد توصيات خاصة لحفظ الدواء.</p><p dir="RTL">لا تتخلص من أي مواد دوائية في مياه المجاري العامة أو مع قمامة المنزل. اسأل الصيدلاني عن طريقة التخلص من الأدوية التي لم تعد بحاجةإليها.&nbsp; هذه الإجراءات تساعد على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">ما هي مكونات تريبليكسام ٥ ملغ/١٫٢٥ ملغ/٥ ملغ حبّات ملبّسة&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المواد الفعالة في كل حبّة ملبّسة تريبليكسام ٥ ملغ/١٫٢٥ ملغ/٥ ملغ هي:</p><p dir="RTL">بيريندوبريل &nbsp;.............................................................................. ٣٫٣٩٥ ملغ</p><p dir="RTL">على شكل بيريندوبريل أرجينين................................................................... ٥ ملغ</p><p dir="RTL">إنداباميد ........................................................................................................................................................................................ .............. .١٫٢٥ ملغ &nbsp;</p><p dir="RTL">أملوديبين......................................................................................... ٥ ملغ</p><p dir="RTL">على شكل بيسيلات الأملوديبين............................................................. ٦٫٩٣٥ ملغ</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المواد الفعالة في كل حبّة ملبّسة تريبليكسام ٥ ملغ/١٫٢٥ ملغ 10 ملغ هي:</p><p dir="RTL">بيريندوبريل &nbsp;.............................................................................. ٣٫٣٩٥ ملغ</p><p dir="RTL">على شكل بيريندوبريل أرجينين................................................................... ٥ ملغ</p><p dir="RTL">إنداباميد ........................................................................................................................................................................................ .............. .١٫٢٥ ملغ &nbsp;</p><p dir="RTL">أملوديبين........................................................................................ ١٠ ملغ</p><p dir="RTL">على شكل بيسيلات الأملوديبين........................................................... ١٣٬٨٧٠ ملغ</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المواد الفعالة في كل حبّة ملبّسة تريبليكسام ١٠ ملغ/٢٬٥ ملغ/٥ ملغ هي:</p><p dir="RTL">بيريندوبريل &nbsp;.............................................................................. ٦٬٧٩٠ ملغ</p><p dir="RTL">على شكل بيريندوبريل أرجينين................................................................. ١٠ ملغ</p><p dir="RTL">إنداباميد .......................................................................................................................................................................................... .............. .٢٬٥ ملغ &nbsp;</p><p dir="RTL">أملوديبين......................................................................................... ٥ ملغ</p><p dir="RTL">على شكل بيسيلات الأملوديبين............................................................. ٦٫٩٣٥ ملغ</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المواد الفعالة في كل حبّة ملبّسة تريبليكسام ١٠ ملغ/٢٬٥ ملغ/١٠ ملغ هي:</p><p dir="RTL">بيريندوبريل &nbsp;............................................................................... ٦٬٧٩٠ملغ</p><p dir="RTL">على شكل بيريندوبريل أرجينين................................................................. ١٠ ملغ</p><p dir="RTL">إنداباميد ......................................................................................................................................................................................... .............. . ٢٬٥ ملغ &nbsp;</p><p dir="RTL">أملوديبين......................................................................................... ١٠ ملغ</p><p dir="RTL">على شكل بيسيلات الأملوديبين........................................................... ١٣٬٨٧٠ ملغ</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المكونات الأخرى هي:</p><p dir="RTL">في نواة الحبّة: مركب النشاء وكربونات الكالسيوم: (كربونات الكالسيوم (٩٠٪)، نشاء الذرة المسبق التهليم (١٠٪))، مكروكريستالين السللوز (إي ٤٦٠)، الكروسكارميلوز الصودي (إي ٤٦٨)، ستيارات المغنيزيوم (إي ٥٧٢)، السيليكا الغروانيّة اللامائيّة، نشاء مسبق التهليم.&nbsp;</p><p dir="RTL">في مادة تلبيس الحبّة: غليسيرول (إي ٤٢٢)، هيبروملوز 6CP (إي ٤٦٤)، ماكروغول ٦٠٠٠، ستيارات المغنيزيوم (إي ٥٧٢)، ثاني أكسيد التيتان (إي ١٧١).&nbsp;&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يتوفر هذا الدواء بشكل حبّات بيضاء، ملبّسة، متطاولة، يبلغ طولها ٩٫٧٥ ملمتر وعرضها ٥٫١٦ ملمتر، نُقش <!--[if gte vml 1]><v:shapetype id="_x0000_t75" coordsize="21600,21600"
 o:spt="75" o:preferrelative="t" path="m@4@5l@4@11@9@11@9@5xe" filled="f"
 stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="Image_x0020_3" o:spid="_x0000_i1025" type="#_x0000_t75"
 style='width:23.5pt;height:11.5pt;visibility:visible'>
 <v:imagedata src="file:///C:/Users/HNHZ_SA1/AppData/Local/Temp/msohtmlclip1/01/clip_image001.emz"
  o:title=""/>
</v:shape><![endif]--><img width="31" height="15" src="file:///C:/Users/HNHZ_SA1/AppData/Local/Temp/msohtmlclip1/01/clip_image002.png" />&nbsp;على أحد وجهيها شكل&nbsp; ، و <!--[if gte vml 1]><v:shape id="_x0000_i1026" type="#_x0000_t75"
 style='width:11.5pt;height:11.5pt;visibility:visible'>
 <v:imagedata src="file:///C:/Users/HNHZ_SA1/AppData/Local/Temp/msohtmlclip1/01/clip_image003.png"
  o:href="cid:image002.png@01CE294D.AFEC90A0"/>
</v:shape><![endif]--><img width="15" height="15" src="file:///C:/Users/HNHZ_SA1/AppData/Local/Temp/msohtmlclip1/01/clip_image004.png" />&nbsp;على الوجه الآخر.&nbsp;</p><p dir="RTL">تتوفر الحبّات في علبة تحتوي على ١٠، ٢٨، ٣٠، ٦٠ (حاويتا أقراص تحوي كل منهما على ٣٠ حبة)، ٨٤ (٣ حاويات أقراص تحوي كل منها على ٢٨ حبة)، ٩٠ (٣ حاويات أقراص تحوي كل منها على ٣٠ حبة)، ١٠٠ و٥٠٠ حبة (٥ حاويات أقراص تحوي كل منها على ١٠٠ حبة).</p><p dir="RTL">يوجد المجفّف ضمن عبوة حاوية الأقراص.</p><p dir="RTL">قد لا تتوفر في السوق جميع أحجام العبوات.&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مختبرات سيرفييه - فرنسا&nbsp;&nbsp;</p><p>LES LABORATOIRES SERVIER</p><p>50, RUE CARNOT</p><p>92284 SURESNES CEDEX</p><p>FRANCE</p><p dir="RTL">الجهة المصنعة:</p><p>SERVIER (IRELAND) INDUSTRIES LTD</p><p>GOREY ROAD</p><p>ARKLOW - CO.WICKLOW</p><p>IRLAND</p><p dir="RTL">&nbsp;</p><p dir="RTL">للحصول على أي معلومات تتعلق بهذا الدواء، الرجاء الاتصال بالوكيل المحلي للجهة الحاملة لإجازة التسويق.</p><p dir="RTL"><strong>&nbsp;</strong></p><table dir="rtl" border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL"><strong>المملكة العربية السعودية</strong></p><p dir="RTL">المكتب العلمي لشركة سيرفير العربية السعودية</p><p dir="RTL">3533 الحوي ، حي حطين، مكتب 101</p><p dir="RTL">المملكة العربية السعودية</p><p dir="RTL">هاتف: ٩٦٦١١2522330+</p><p dir="RTL">البريد الالكتروني: regulatory.sa1@servier.com</p></td><td style="vertical-align:top"><p dir="RTL"><strong>بلدان الخليج</strong></p><p dir="RTL">المكتب العلمي لمختبرات سيرفييه</p><p dir="RTL">ص.ب. ١٥٨٦، الطابق 15، برج أرينكو، مدينة دبي الإعلامية</p><p dir="RTL">طريق الشيخ زايد، دبي، الإمارات العربية المتحدة</p><p dir="RTL">هاتف: ٩٧١٤٣٣٢٩٩٠٣+</p><p dir="RTL">البريد الالكتروني: <u>magdy.abdou@servier.com</u></p><p dir="RTL"><strong>&nbsp;</strong></p></td></tr></tbody></table><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>&nbsp;</strong></p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت المراجعة الأخيرة لهذه النشرة بتاريخ 9-2022 

للإبلاغ عن التأثير(ات) الجانبية:

•	المملكة العربية السعودية

- المركز الوطني للتيقظ الدوائي (NPC)
- للاتصال بالرقم الموحد للهيئة العامة للغذاء والدواء 19999
- البريد الالكتروني: npc.drug@sfda.gov.sa
- الموقع الالكتروني: https://ade.sfda.gov.sa/ 

•	دول الخليج العربي الأخرى:
- الرجاء الاتصال بالسلطات المختصة ذات الصلة.

مجلس وزراء الصحة العرب:

إن هذا لدواء
-	الدواء مستحضر يؤثر على صحّتك، واستهلاكه خلافاً للتعليمات يعرّضك للخطر.
-	تقيّد بوصفة الطبيب، وبطريقة الاستعمال المدوّنة، وبتعليمات الصيدلاني الذي صرف لك الدواء.
-	فالطبيب والصيدلاني هما الخبيران بالدواء ونفعه وضرره.
-	لا تقطع مدة العلاج الموصوفة لك من تلقاء نفسك.
-	لا تكرر استعمال نفس الدواء دون مراجعة الطبيب.
-	لا تدع الأدوية بمتناول أيدي الأطفال.
                                                      مجلس وزراء الصحّة العرب
                                               وإتّحاد الصيادلة العرب

هذه النشرة لمعلومات المريض حائزة على موافقة الهيئة العامة للغذاء والدواء في المملكة العربية السعودية




        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Triplixam 5mg/1.25mg/5mg film-coated tablets
Triplixam 5mg/1.25mg/10mg film-coated tablets
Triplixam 10mg/2.5mg/5mg film-coated tablets
Triplixam 10mg/2.5mg/10mg film-coated tablets

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                One film-coated tablet contains 3.395 mg perindopril equivalent to 5 mg perindopril arginine, 1.25 mg indapamide and 6.935 mg amlodipine besilate equivalent to 5 mg of amlodipine.
One film-coated tablet contains 3.395 mg perindopril equivalent to 5 mg perindopril arginine, 1.25 mg indapamide and 13.870 mg amlodipine besilate equivalent to 10mg of amlodipine.
One film-coated tablet contains 6.790 mg perindopril equivalent to 10 mg perindopril arginine, 2.5 mg indapamide and 6.935 mg amlodipine besilate equivalent to 5 mg of amlodipine.
One film-coated tablet contains 6.790 mg perindopril equivalent to 10 mg perindopril arginine, 2.5 mg indapamide and 13.870 mg amlodipine besilate equivalent to 10 mg of amlodipine.
For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated tablet.

Triplixam 5/1.25/5 mg: white, oblong, film-coated tablet, 9.75 mm long and 5.16 mm wide, engraved with   on one face and  on the other face.
Triplixam 5/1.25/10 mg: white, oblong, film-coated tablet, 10.7 mm long and 5.66 mm wide, engraved with   on one face and  on the other face.
Triplixam 10/2.5/5 mg: white, oblong, film-coated tablet, 11.5 mm long and 6.09 mm wide, engraved with   on one face and  on the other face.
Triplixam 10/2.5/10 mg: white, oblong, film-coated tablet, 12.2 mm long and 6.46 mm wide, engraved with  on one face and   on the other face.


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Triplixam is indicated as substitution therapy for treatment of essential hypertension, in patients already controlled with perindopril/indapamide fixed dose combination and amlodipine, taken at the same dose level.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u></p><p>One Triplixam film-coated tablet per day as a single dose, preferably to be taken in the morning and before a meal<em>.</em></p><p>&nbsp;</p><p>The fixed dose combination is not suitable for initial therapy.</p><p>If a change of the posology is required, titration should be done with the individual components.</p><p>&nbsp;</p><p><u>Special population</u></p><p><u>&nbsp;</u></p><p><em>Renal impairment (see section 4.3 and 4.4)</em></p><p>In severe renal impairment (creatinine clearance below 30 mL/min), treatment is contraindicated.</p><p>In patients with moderate renal impairment (creatinine clearance 30-60 mL/min), Triplixam at the doses 10mg/2.5mg /5mg and 10mg/2.5mg/10mg is contraindicated. I t is recommended to start treatment with the adequate dosage of the free combination.</p><p>Usual medical follow-up will include frequent monitoring of creatinine and potassium.</p><p>Concomitant use of perindopril with aliskiren is contraindicated in patients with renal impairment (GFR &lt; 60 ml/min/1.73 m2) (see section 4.3).</p><p>&nbsp;</p><p><em>Hepatic impairment (see sections 4.3, 4.4 and 5.2)</em></p><p>In severe hepatic impairment, Triplixam is contraindicated.</p><p>&nbsp;</p><p>In patients with mild to moderate hepatic impairment, Triplixam should be administrated with caution, as dosage recommendations for amlodipine in these patients have not been established.</p><p><em>&nbsp;</em></p><p><em>Elderly (see section 4.4)</em></p><p>Elimination of perindoprilat is decreased in the elderly (see Section 5.2).</p><p>Elderly can be treated with Triplixam according to renal function (see Section 4.3).</p><p>&nbsp;</p><p><em>Paediatric population</em></p><p>The safety and efficacy of Triplixam in children and adolescents have not been established. No data are available.</p><p>&nbsp;</p><p><u>Method of administration</u></p><p><strong>&nbsp;</strong></p><p>Oral use.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                -	Dialysis patients
-	Patients with untreated decompensated heart failure
-	Severe renal impairment (creatinine clearance below 30 mL/min) 
-	Moderate renal impairment (creatinine clearance below 60 mL/min) for Triplixam doses containing 10mg/2.5mg of perindopril/indapamide combination (i.e., Triplixam 10mg/2.5mg/5mg and 10mg/2.5mg/10mg)
-  	Hypersensitivity to the active substances, to other sulfonamides, to dihydropyridine derivatives, any 	other ACE-inhibitor or to any of the excipients listed in section 6.1.
-	History of angioedema (Quincke’s oedema) associated with previous ACE inhibitor therapy (see section 4.4)
-	Hereditary/idiopathic angioedema 
-	Second and third trimesters of pregnancy (see sections 4.4 and 4.6)
-	Hepatic encephalopathy
-	Severe hepatic impairment
-	Hypokalaemia
-	Severe hypotension
-	Shock, including cardiogenic shock
-	Obstruction of the outflow-tract of the left ventricle (e.g. high grade aortic stenosis)
-	Haemodynamically unstable heart failure after acute myocardial infarction
-	Concomitant use of Triplixam with aliskiren-containing products  in patients with diabetes mellitus or renal impairment (GFR < 60mL/min/1.73m2) (See sections 4.5 and 5.1)
-	Concomitant use with sacubitril/valsartan therapy. Triplixam must not be initiated earlier than 36 hours after the last dose of sacubitril/valsartan (see sections 4.4 and 4.5).
-	Extracorporeal treatments leading to contact of blood with negatively charged surfaces (see section 4.5),
-	Significant bilateral renal artery stenosis or stenosis of the artery to a single functioning kidney (see section 4.4).

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>All warnings related to each component, as listed below, should apply also to the fixed combination of Triplixam.</p><p>&nbsp;</p><p><strong><em><u>Special warnings</u></em></strong></p><p><em><u>&nbsp;</u></em></p><p><u>Lithium</u></p><p>The combination of lithium and the combination of perindopril/indapamide is usually not recommended (see section 4.5).</p><p>&nbsp;</p><p><u>Dual blockade of the renin-angiotensin-aldosterone system (RAAS) </u></p><p>There is evidence that the concomitant use of ACE-inhibitors, angiotensin II receptor blockers or aliskiren increases the risk of hypotension, hyperkalaemia and decreased renal function (including acute renal failure). Dual blockade of RAAS through the combined use of ACE-inhibitors, angiotensin II receptor blockers or aliskiren is therefore not recommended (see sections 4.5 and 5.1).</p><p>If dual blockade therapy is considered absolutely necessary, this should only occur under specialist supervision and subject to frequent close monitoring of renal function, electrolytes and blood pressure.</p><p>ACE-inhibitors and angiotensin II receptor blockers should not be used concomitantly in patients with diabetic nephropathy.</p><p>&nbsp;</p><p><u>Potassium-sparing&nbsp; drugs, potassium </u><u>supplements or potassium-containing</u><u> salt substitutes </u></p><p>The combination of perindopril and potassium-sparing&nbsp; drugs, potassium supplements or potassium-containing salt substitutes is usually not recommended (see section 4.5).</p><p>&nbsp;</p><p><u>Neutropenia/agranulocytosis</u><u>/thrombocytopenia/anaemia</u></p><p>Neutropenia/agranulocytosis, thrombocytopenia and anaemia have been reported in patients receiving ACE inhibitors. In patients with normal renal function and no other complicating factors, neutropenia occurs rarely. Perindopril should be used with extreme caution in patients with collagen vascular disease, immunosuppressant therapy, treatment with allopurinol or procainamide, or a combination of these complicating factors, especially if there is pre-existing impaired renal function. Some of these patients developed serious infections which in a few instances did not respond to intensive antibiotic therapy. If perindopril is used in such patients, periodical monitoring of white blood cell counts is advised and patients should be instructed to report any sign of infection (e.g. sore throat, fever) (see section 4.8).</p><p>&nbsp;</p><p><u>Renovascular hypertension:</u></p><p>There is an increased risk of hypotension and renal insufficiency when patient with bilateral renal artery stenosis or stenosis of the artery to a single functioning kidney are treated with ACE inhibitors (see section 4.3). Treatment with diuretics may be a contributory factor. Loss of renal function may occur with only minor changes in serum creatinine even in patients with unilateral renal artery stenosis.</p><p>&nbsp;</p><p><u>Hypersensitivity/angioedema</u></p><p>Angioedema of the face, extremities, lips, tongue, glottis and/or larynx has been reported rarely in patients treated with angiotensin converting enzyme inhibitors, including&nbsp;perindopril. This may occur at any time during treatment. In such cases perindopril&nbsp;should be discontinued promptly and appropriate monitoring should be instituted to ensure complete resolution of symptoms prior to dismissing the patient. In those instances where swelling has been confined to the face and lips the condition generally resolved without treatment, although antihistamines have been useful in relieving symptoms.</p><p>Angioedema associated with laryngeal oedema may be fatal. Where there is involvement of the tongue, glottis or larynx, likely to cause airway obstruction, appropriate therapy, which may include subcutaneous epinephrine solution 1:1000 (0.3&nbsp;mL to 0.5&nbsp;mL) and/or measures to ensure a patent airway, should be administered promptly.</p><p>&nbsp;</p><p>Black patients receiving ACE inhibitors have been reported to have a higher incidence of angioedema compared to non-blacks.</p><p>&nbsp;</p><p>Patients with a history of angioedema unrelated to ACE inhibitor therapy may be at increased risk of angioedema while receiving an ACE&nbsp;inhibitor (see section 4.3).</p><p>&nbsp;</p><p>Intestinal angioedema has been reported rarely in patients treated with ACE inhibitors. These patients presented with abdominal pain (with or without nausea or vomiting); in some cases there was no prior facial angioedema and C-1 esterase levels were normal. The angioedema was diagnosed by procedures including abdominal CT scan, or ultrasound or at surgery and symptoms resolved after stopping the ACE inhibitor. Intestinal angioedema should be included in the differential diagnosis of patients on ACE inhibitors presenting with abdominal pain.</p><p>&nbsp;</p><p>The combination of perindopril with sacubitril/valsartan is contraindicated due to the increased risk of angioedema (see section 4.3). Sacubitril/valsartan must not be initiated until 36 hours after taking the last dose of perindopril therapy. If treatment with sacubitril/valsartan is stopped, perindopril therapy must not be initiated until 36 hours after the last dose of sacubitril/valsartan (see sections 4.3 and 4.5).</p><p>Concomitant use of ACE inhibitors with NEP inhibitors (e.g. racecadotril), mTOR inhibitors (e.g. sirolimus, everolimus, temsirolimus) and gliptins (e.g. linagliptin, saxagliptin, sitagliptin, vildagliptin) may lead to an increased risk of angioedema (e.g. swelling of the airways or tongue, with or without respiratory impairment) (see section 4.5). Caution should be used when starting racecadotril, mTOR inhibitors (e.g. sirolimus, everolimus, temsirolimus) and gliptins (e.g. linagliptin, saxagliptin, sitagliptin, vildagliptin) in a patient already taking an ACE inhibitor.</p><p>&nbsp;</p><p><u>Anaphylactoid reactions during desensitization</u></p><p>There have been isolated reports of patients experiencing sustained, life-threatening anaphylactoid reactions while receiving ACE inhibitors during desensitisation treatment with hymenoptera (bees, wasps) venom. ACE inhibitors should be used with caution in allergic patients treated with desensitisation, and avoided in those undergoing venom immunotherapy. However these reactions could be prevented by temporary withdrawal of ACE inhibitor for at least 24 hours before treatment in patients who require both ACE inhibitors and desensitisation.</p><p>&nbsp;</p><p><u>Anaphylactoid reactions during LDL apheresis </u></p><p>Rarely, patients receiving ACE inhibitors during low density lipoprotein (LDL)-apheresis with dextran sulphate have experienced life-threatening anaphylactoid reactions. These reactions were avoided by temporarily withholding ACE-inhibitor therapy prior to each apheresis.</p><p>&nbsp;</p><p><u>Haemodialysis patients</u></p><p>Anaphylactoid reactions have been reported in patients dialysed with high-flux membranes (e.g., AN 69&reg;) and treated concomitantly with an ACE inhibitor. In these patients consideration should be given to using a different type of dialysis membrane or a different class of antihypertensive agent.</p><p>&nbsp;</p><p><u>Primary aldosteronism:</u></p><p>Patients with primary hyperaldosteronism generally will not respond to anti-hypertensive drugs acting through inhibition of the renin-angiotensin system. Therefore, the use of this product is not recommended.</p><p>&nbsp;</p><p><u>Pregnancy</u></p><p>ACE inhibitors should not be initiated during pregnancy. Unless continued ACE inhibitor therapy is considered essential, patients planning pregnancy should be changed to alternative anti-hypertensive treatments which have an established safety profile for use in pregnancy. When pregnancy is diagnosed, treatment with ACE inhibitors should be stopped immediately, and, if appropriate, alternative therapy should be started (see sections 4.3 and 4.6).</p><p>&nbsp;</p><p><u>Hepatic encephalopathy</u></p><p>When liver function is impaired, thiazide diuretics and thiazide-related diuretics may cause, particularly in case of electrolyte imbalance, hepatic encephalopathy which can progress to coma.. Administration of the diuretic should be stopped immediately if this occurs.</p><p>&nbsp;</p><p><u>Photosensitivity </u></p><p>Cases of photosensitivity reactions have been reported with thiazides and related thiazides diuretics (see section 4.8). If photosensitivity reaction occurs during treatment, it is recommended to stop the treatment. If a re-administration of the diuretic is deemed necessary, it is recommended to protect exposed areas to the sun or to artificial UVA.</p><p><em><u>&nbsp;</u></em></p><p><strong><em><u>Precautions for use</u></em></strong></p><p>&nbsp;</p><p><u>Renal function</u></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In cases of severe renal impairment (creatinine clearance &lt; 30 mL/min), treatment is contraindicated.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; For patients with a moderate renal impairment (creatinine clearance &lt; 60 mL/min), treatment is contraindicated with Triplixam doses containing 10mg/2.5mg of perindopril /indapamide combination (i.e., Triplixam 10mg/2.5mg /5mg and 10mg/2.5mg/10mg).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In certain hypertensive patients without pre-existing apparent renal lesions and for whom renal blood tests show functional renal insufficiency, treatment should be stopped and possibly restarted either at a low dose or with one constituent only.</p><p>In these patients usual medical follow-up will include frequent monitoring of potassium and creatinine, after two weeks of treatment and then every two months during therapeutic stability period. Renal failure has been reported mainly in patients with severe heart failure or underlying renal failure including renal artery stenosis.</p><p>The drug is usually not recommended in case of bilateral renal artery stenosis or a single functioning kidney.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Risk of arterial hypotension and/or renal insufficiency (in cases of cardiac insufficiency , water and electrolyte depletion, etc&hellip;): Marked stimulation of the renin-angiotensin-aldosterone system has been observed with perindopril particularly during marked water and electrolyte depletions (strict sodium restricted diet<strong><em> </em></strong>or prolonged diuretic treatment), in patients whose blood pressure was initially low, in cases of renal artery stenosis, congestive heart failure or cirrhosis with oedema and ascites.</p><p>The blocking of this system with an angiotensin converting enzyme inhibitor may therefore cause, particularly at the time of the first administration and during the first two weeks of treatment, a sudden drop in blood pressure and/or an increase in plasma levels of creatinine, showing a functional renal insufficiency. Occasionally this can be acute in onset, although rare, and with a variable time to onset.</p><p>In such cases, the treatment should then be initiated at a lower dose and increased progressively.In patients with ischaemic heart or cerebrovascular disease an excessive fall in blood pressure could result in a myocardial infarction or cerebrovascular accident.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Thiazide diuretics and thiazide-related diuretics are only fully effective when renal function is normal or only slightly impaired (creatinine levels lower than approximately 25 mg/l, i.e. 220&nbsp;&micro;mol/l for an adult).</p><p>In the elderly the value of plasma creatinine levels should be adjusted in relation to age, weight and gender.</p><p>Hypovolaemia, secondary to the loss of water and sodium caused by the diuretic at the start of treatment, causes a reduction in glomerular filtration. It may result in an increase in blood urea and creatinine levels. This transitory functional renal insufficiency is of no adverse consequence in patients with normal renal function but may however worsen a pre-existing renal impairment.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Amlodipine may be used at normal doses in patients with renal failure. Changes in amlodipine plasma concentrations are not correlated with degree of renal impairment.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The effect of the combination Triplixam has not been tested in renal dysfunction. In renal impairment, Triplixam doses should respect those of the individual components taken separately.</p><p>&nbsp;</p><p><u>Hypotension and water and sodium depletion </u></p><p>- &nbsp;&nbsp; There is a risk of sudden hypotension in the presence of pre-existing sodium depletion (in particular in individuals with renal artery stenosis). Therefore systematic testing should be carried out for clinical signs of water and electrolyte depletion, which may occur with an intercurrent episode of diarrhoea or vomiting. Regular monitoring of plasma electrolytes should be carried out in such patients.</p><p>Marked hypotension may require the implementation of an intravenous infusion of isotonic saline.</p><p>Transient hypotension is not a contraindication to continuation of treatment. After re‑establishment of a satisfactory blood volume and blood pressure, treatment can be started again either at a reduced dose or with only one of the constituents.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Reduction in sodium levels can be initially asymptomatic and regular testing is therefore essential. Testing should be more frequent in elderly and cirrhotic patients (see sections 4.8 and 4.9).</p><p>Any diuretic treatment may cause hyponatraemia, sometimes with very serious consequences.</p><p>Hyponatraemia with hypovolaemia may be responsible of dehydration and orthostatic hypotension. Concomitant loss of chloride ions may lead to secondary compensatory metabolic alkalosis: the incidence and degree of this effect are slight.</p><p>&nbsp;</p><p><u>Potassium levels </u></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The combination of indapamide with perindopril and amlodipine does not prevent the onset of hypokalaemia particularly in diabetic patients or in patients with renal failure. As with any antihypertensive agent in combination with a diuretic, regular monitoring of plasma potassium levels should be carried out.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Elevations in serum potassium have been observed in some patients treated with ACE inhibitors, including perindopril, ACE inhibitors can cause hyperkalaemia because they inhibit the release of aldosterone. The effect is usually not significant in patients with normal renal function. Risk factors for the development of hyperkalemia include those with renal insufficiency, worsening of renal function, age (&gt; 70 years), diabetes mellitus, intercurrent events, in particular dehydration, acute cardiac decompensation, metabolic acidosis and concomitant use of potassium-sparing diuretics (e.g., spironolactone, eplerenone, triamterene, or amiloride), potassium supplements or potassium-containing salt substitutes; or those patients taking other drugs associated with increases in serum potassium (e.g. heparin, co-trimoxazole also known as trimethoprim/sulfamethoxazole) and especially aldosterone antagonists or angiotensin-receptor blockers. The use of potassium supplements, potassium-sparing diuretics, or potassium-containing salt substitutes particularly in patients with impaired renal function may lead to a significant increase in serum potassium. Hyperkalemia can cause serious, sometimes fatal arrhythmias.<strong><em> </em></strong>Potassium-sparing diuretics and angiotensin-receptor blockers should be used with caution in patients receiving ACE inhibitors, and serum potassium and renal function should be monitored. If concomitant use of the above-mentioned agents is deemed appropriate, they should be used with caution and with frequent monitoring of serum potassium (see section 4.5).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Potassium depletion with hypokalaemia is a major risk with thiazide diuretics and thiazide-related diuretics. Hypokalaemia may cause muscle disorders. Cases of Rhabdomyolysis have been reported, mainly in the context of severe hypokalaemia. The risk of onset of lowered potassium levels (&lt;&nbsp;3.4&nbsp;mmol/l) should be prevented in some high risk populations such as elderly and/or malnourished subjects, whether or not they are taking multiple medications, cirrhotic patients with oedema and ascites, coronary patients and patients with heart failure.</p><p>In such cases hypokalaemia increases the cardiac toxicity of cardiac glycosides and the risk of rhythm disorders.</p><p>Subjects presenting with a long QT interval are also at risk, whether the origin is congenital or iatrogenic. Hypokalaemia, as with bradycardia, acts as a factor which favours the onset of severe rhythm disorders, in particular torsades de pointes, which may be fatal.</p><p>In all cases more frequent testing of potassium levels is necessary. The first measurement of plasma potassium levels should be carried out during the first week following the start of treatment.</p><p>If low potassium levels are detected, correction is required. Hypokalaemia found in association with low serum magnesium concentration can be refractory to treatment unless serum magnesium is corrected.</p><p>&nbsp;</p><p><u>Calcium levels</u></p><p>Thiazide diuretics and thiazide-related diuretics may reduce urinary excretion of calcium and cause a mild and transient increase in plasma calcium levels. Markedly raised levels of calcium may be related to undiagnosed hyperparathyroidism. In such cases the treatment should be stopped before investigating the parathyroid function (see section 4.8).</p><p>&nbsp;</p><p>Plasma magnesium:</p><p>Thiazides and related diuretics including indapamide have been shown to increase the urinary excretion of magnesium, which may result in hypomagnesaemia (see section 4.5 and 4.8).</p><p>&nbsp;</p><p>&nbsp;</p><p><u>Renovascular hypertension</u></p><p>The treatment for renovascular hypertension is revascularisation. Nonetheless, angiotensin converting enzyme inhibitors can be beneficial in patients presenting with renovascular hypertension who are awaiting corrective surgery or when such a surgery is not possible.</p><p>If Triplixam is prescribed to patients with known or suspected renal artery stenosis, treatment should be started in a hospital setting<strong><em> </em></strong>at a low dose and renal function and potassium levels should be monitored, since some patients have developed a functional renal insufficiency which was reversed when treatment was stopped.</p><p>&nbsp;</p><p>&nbsp;</p><p><u>Cough</u></p><p>A dry cough has been reported with the use of angiotensin converting enzyme inhibitors. It is characterised by its persistence and by its disappearance when treatment is withdrawn. An iatrogenic aetiology should be considered in the event of this symptom. If the prescription of an angiotensin converting enzyme inhibitor is still preferred, continuation of treatment may be considered.</p><p><em>&nbsp;</em></p><p><u>Atherosclerosis</u></p><p>The risk of hypotension exists in all patients but particular care should be taken in patients with ischaemic heart disease or cerebral circulatory insufficiency, with treatment being started at a low dose.</p><p>&nbsp;</p><p><u>Hypertensive crisis</u></p><p>The safety and efficacy of amlodipine in hypertensive crisis has not been established.</p><p><em>&nbsp;</em></p><p><u>Cardiac failure</u><u>/severe cardiac insufficiency</u></p><p>Patients with heart failure should be treated with caution.</p><p>In a long-term, placebo controlled study in patients with severe heart failure (NYHA class III and IV) the reported incidence of pulmonary oedema was higher in the amlodipine treated group than in the placebo group. Calcium channel blockers, including amlodipine, should be used with caution in patients with congestive heart failure, as they may increase the risk of future cardiovascular events and mortality.</p><p>In patients with severe cardiac insufficiency (grade IV) treatment should be started under medical supervision with a reduced initial dose. Treatment with beta-blockers in hypertensive patients with coronary insufficiency should not be stopped: the ACE inhibitor should be added to the beta-blocker.</p><p>&nbsp;</p><p><u>Aortic or mitral valve stenosis / hypertrophic cardiomyopathy</u></p><p>ACE inhibitors should be used with caution in patient with an obstruction in the outflow tract of the left ventricle.</p><p>&nbsp;</p><p><u>Diabetic patients</u></p><p>In patients with insulin dependent diabetes mellitus (spontaneous tendency to increased levels of potassium), treatment should be started under medical supervision with a reduced initial dose.</p><p>The glycaemia levels should be closely monitored in diabetic patients previously treated with oral antidiabetic drugs or insulin, namely during the first month of treatment with an ACE inhibitor.</p><p>Monitoring of blood glucose is important in diabetic patients, particularly when potassium levels are low.</p><p>&nbsp;</p><p><u>Ethnic differences</u></p><p>As with other angiotensin converting enzyme inhibitors, perindopril is apparently less effective in lowering blood pressure in black people than in non‑blacks, possibly because of a higher prevalence of low-renin states in the black hypertensive population.</p><p>&nbsp;</p><p><u>Surgery / anaesthesia</u></p><p>Angiotensin converting enzyme inhibitors can cause hypotension in cases of anaesthesia, especially when the anaesthetic administered is an agent with hypotensive potential.</p><p>It is therefore recommended that treatment with long-acting angiotensin converting enzyme inhibitors such as perindopril should be discontinued where possible one day before surgery.</p><p>&nbsp;</p><p><u>Hepatic impairment</u></p><p>Rarely, ACE inhibitors have been associated with a syndrome that starts with cholestatic jaundice and progresses to fulminant hepatic necrosis and (sometimes) death. The mechanism of this syndrome is not understood. Patients receiving ACE inhibitors who develop jaundice or marked elevations of hepatic enzymes should discontinue the ACE inhibitor and receive appropriate medical follow-up (see section 4.8).</p><p>&nbsp;</p><p>The half-life of amlodipine is prolonged and AUC values are higher in patients with impaired liver function; dosage recommendations have not been established. Amlodipine should therefore be initiated at the lower end of the dosing range and caution should be used, both on initial treatment and when increasing the dose. Slow dose titration and careful monitoring may be required in patients with severe hepatic impairment.</p><p>&nbsp;</p><p>The effect of the combination Triplixam has not been tested in hepatic dysfunction. Taking into account the effect of each individual component of this combination, Triplixam is contraindicated in patients with severe hepatic impairment, and caution should be exercised in patients with mild to moderate hepatic impairment.</p><p>&nbsp;</p><p><u>Uric acid</u></p><p>Tendency to gout attacks may be increased in hyperuricaemic patients.</p><p>&nbsp;</p><p><u>Elderly</u></p><p>Renal function and potassium levels should be tested before the start of treatment. The initial dose is subsequently adjusted according to blood pressure response, especially in cases of water and electrolyte depletion, in order to avoid sudden onset of hypotension.</p><p>In the elderly increase of the dosage of amlodipine should take place with care (see sections 4.2 and 5.2).</p><p><u>&nbsp;</u></p><p><u>Excipients</u></p><p>Level of sodium</p><p>Triplixam contains less than 1 mmol sodium (23 mg) per tablet, i.e. essentially &lsquo;sodium-free&rsquo;.</p><p>&nbsp;</p><p><u>Choroidal effusion, acute myopia and secondary angle-closure glaucoma</u></p><p>Sulfonamide or sulfonamide derivative drugs can cause an idiosyncratic reaction resulting in choroidal effusion with visual field defect, transient myopia and acute angle-closure glaucoma. Symptoms include acute onset of decreased visual acuity or ocular pain and typically occur within hours to weeks of drug initiation. Untreated acute angle-closure glaucoma can lead to permanent vision loss. The primary treatment is to discontinue drug intake as rapidly as possible. Prompt medical or surgical treatments may need to be considered if the intraocular pressure remains uncontrolled. Risk factors for developing acute angle-closure glaucoma may include a history of sulfonamide or penicillin allergy.</p><p>&nbsp;</p><p><u>Athletes</u></p><p>Athletes should note that this product contains an active substance which may cause a positive reaction in doping tests.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Clinical trial data has shown that dual blockade of the renin-angiotensin-aldosterone-system (RAAS) through the combined use of ACE-inhibitors, angiotensin II receptor blockers or aliskiren is associated with a higher frequency of adverse events such as hypotension, hyperkalaemia and decreased renal function (including acute renal failure) compared to the use of a single RAAS-acting agent (see sections 4.3, 4.4 and 5.1).</p><p><strong>&nbsp;</strong></p><p><em>Drugs increasing the risk of angioedema: </em></p><p>Concomitant use of ACE inhibitors with sacubitril/valsartan is contraindicated as this increases the risk of angioedema (see section 4.3 and 4.4). Sacubitril/valsartan must not be started until 36 hours after taking the last dose of perindopril therapy. Perindopril therapy must not be started until 36 hours after the last dose of sacubitril/valsartan (see sections 4.3 and 4.4).</p><p>Concomitant use of ACE inhibitors with racecadotril, mTOR inhibitors (e.g. sirolimus, everolimus, temsirolimus) and gliptins (e.g. linagliptin, saxagliptin, sitagliptin, vildagliptin) may lead to an increased risk for angioedema (see section 4.4).</p><p>&nbsp;</p><p><em>Drugs inducing hyperkalaemia:</em></p><p>Although serum potassium usually remains within normal limits, hyperkalaemia may occur in some patients treated with Triplixam. Some drugs or therapeutic classes may increase the occurrence of hyperkalaemia: aliskiren, potassium salts, potassium-sparing diuretics (e.g. spironolactone, triamterene or amiloride), ACE inhibitors, angiotensin-II receptors antagonists, NSAIDs, heparins, immunosuppressant agents such as ciclosporin or tacrolimus, trimethoprim and cotrimoxazole (trimethoprim/sulfamethoxazole), as trimethoprim is known to act as a potassium-sparing diuretic like amiloride. The combination of these drugs increases the risk of hyperkalaemia. Therefore, the combination of Triplixam with the above-mentioned drugs is not recommended. If concomitant use is indicated, they should be used with caution and with frequent monitoring of serum potassium</p><p>&nbsp;</p><p><em>Concomitant use contraindicated (See section 4.3):</em></p><p>Aliskiren: In diabetic or impaired renal patients, risk of hyperkalaemia, worsening of renal function and cardiovascular morbidity and mortality increase.</p><p>&nbsp;</p><p>Extracorporeal treatments : Extracorporeal treatments leading to contact of blood with negatively charged surfaces such as dialysis or haemofiltration with certain high-flux membranes (e.g. polyacrylonitril membranes) and low density lipoprotein apheresis with dextran sulphate due to increased risk of severe anaphylactoid reactions (see section 4.3). If such treatment is required, consideration should be given to using a different type of dialysis membrane or a different class of antihypertensive agent.</p><p>&nbsp;</p><p>&nbsp;</p><p><em>Concomitant use not recommended:</em></p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong><em>Component</em></strong></p></td><td style="vertical-align:top"><p><strong><em>Known interaction with the following product</em></strong></p></td><td style="vertical-align:top"><p><strong><em>Interaction with other medicinal product</em></strong></p></td></tr><tr><td style="vertical-align:top"><p>perindopril / indapamide</p></td><td style="vertical-align:top"><p>Lithium</p></td><td style="vertical-align:top"><p>Reversible increases in serum lithium concentrations and toxicity have been reported during concomitant administration of lithium with ACE&nbsp;inhibitors. Use of perindopril combined with indapamide with lithium is not recommended, but if the combination proves necessary, careful monitoring of serum lithium levels should be performed (see section 4.4).</p></td></tr><tr><td rowspan="4" style="vertical-align:top"><p>perindopril</p></td><td style="vertical-align:top"><p>Aliskiren</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>In patients other than diabetic or impaired renal patients, risk of hyperkalaemia, worsening of renal function and cardiovascular morbidity and mortality increase. (See section 4.4).</p></td></tr><tr><td style="vertical-align:top"><p>Concomitant therapy with ACE inhibitor and angiotensin-receptor blocker</p></td><td style="vertical-align:top"><p>It has been reported in the literature that in patients with established atherosclerotic disease, heart failure, or with diabetes with end organ damage, concomitant therapy with ACE inhibitor and angiotensin-receptor blocker is associated with a higher frequency of hypotension, syncope, hyperkalaemia, and worsening renal function (including acute renal failure) as compared to use of a single renin-angiotensin-aldosterone system agent. Dual blockade (e.g, by combining an ACE-inhibitor with an angiotensin II receptor antagonist) should be limited to individually defined cases with close monitoring of renal function, potassium levels, and blood pressure. (See section 4.4)</p></td></tr><tr><td style="vertical-align:top"><p>Estramustine</p></td><td style="vertical-align:top"><p>Risk of increased adverse effects such as angioneurotic oedema (angioedema).</p></td></tr><tr><td style="vertical-align:top"><p>Potassium-sparing drugs (e.g triamterene,amiloride,&hellip;), potassium (salts),</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Hyperkalaemia (potentially lethal), especially in conjunction with renal impairment (additive hyperkalaemic effects). The combination of perindopril with the above-mentioned drugs is not recommended (see section 4.4). If concomitant use is nonetheless indicated, they should be used with caution and with frequent monitoring of serum potassium. For use of spironolactone in heart failure, see &ldquo;Concomitant use which requires special care&rdquo;.</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>amlodipine</p></td><td style="vertical-align:top"><p>Dantrolene (infusion)</p></td><td style="vertical-align:top"><p>In animals, lethal ventricular fibrillation and cardiovascular collapse are observed in association with hyperkalemia after administration of verapamil and intravenous dantrolene. Due to risk of hyperkalemia, it is recommended that the co-administration of calcium channel blockers such as amlodipine be avoided in patients susceptible to malignant hyperthermia and in the management of malignant hyperthermia</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Grapefruit or grapefruit juice</p></td><td style="vertical-align:top"><p>The bioavailability may be increased in some patients resulting in increased blood pressure lowering effects</p></td></tr></tbody></table><p>&nbsp;</p><p><em>Concomitant use which requires special care:</em></p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:680px"><thead><tr><td style="vertical-align:top"><p><strong><em>Component</em></strong></p></td><td colspan="2" style="vertical-align:top"><p><strong><em>Known interaction with the following product</em></strong></p></td><td style="vertical-align:top"><p><strong><em>Interaction with other medicinal product</em></strong></p></td></tr></thead><tbody><tr><td rowspan="2" style="vertical-align:top"><p>perindopril / indapamide /</p></td><td colspan="2" style="vertical-align:top"><p>Baclofen</p></td><td style="vertical-align:top"><p>Increased antihypertensive effect. Monitor blood pressure and adapt antihypertensive dosage if necessary.</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Non-steroidal anti-inflammatory medicinal products (included&nbsp;acetylsalicylic acid at high doses)</p></td><td style="vertical-align:top"><p>When ACE-inhibitors are administered simultaneously with non-steroidal anti-inflammatory drugs (i.e. acetylsalicylic acid at anti-inflammatory dosage regimens, COX-2 inhibitors and non-selective NSAIDs), attenuation of the antihypertensive effect may occur. Concomitant use of ACE-inhibitors and NSAIDs may lead to an increased risk of worsening of renal function, including possible acute renal failure, and an increase in serum potassium, especially in patients with poor pre-existing renal function. The combination should be administered with caution, especially in the elderly. Patients should be adequately hydrated and consideration should be given to monitoring renal function after initiation of concomitant therapy, and periodically thereafter.</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>perindopril</p></td><td colspan="2" style="vertical-align:top"><p>Antidiabetic agents (insulin, oral hypoglycaemic agents)</p></td><td style="vertical-align:top"><p>&nbsp;Epidemiological studies have suggested that concomitant administration of ACE inhibitors and antidiabetic medicines (insulins, oral hypoglycaemic agents) may cause an increased blood-glucose lowering effect with risk of hypoglycaemia. This phenomenon appeared to be more likely to occur during the first weeks of combined treatment and in patients with renal impairment.</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Non-potassium-sparing diuretics</p></td><td style="vertical-align:top"><p>Patients on diuretics, and especially those who are volume and/or salt depleted, may experience excessive reduction in blood pressure after initiation of therapy with an ACE inhibitor. The possibility of hypotensive effects can be reduced by discontinuation of the diuretic, by increasing volume or salt intake prior to initiating therapy with low and progressive doses of perindopril.</p><p>In arterial hypertension, when prior diuretic therapy can have caused salt/volume depletion, either the diuretic must be discontinued before initiating the ACE inhibitor, in which case a non-potassium-sparing diuretic can be thereafter reintroduced or the ACE inhibitor must be initiated with a low dosage and progressively increased.</p><p>In diuretic-treated congestive heart failure, the ACE inhibitor should be initiated at a very low dosage, possibly after reducing the dosage of the associated non-potassium-sparing diuretic.</p><p>In all cases, renal function (creatinine levels) must be monitored during the first few weeks of ACE inhibitor therapy.</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Potassium-sparing diuretics (eplerenone, spironolactone)</p></td><td style="vertical-align:top"><p>With eplerenone or spironolactone at doses between 12,5 mg to 50 mg by day and with low doses of ACE inhibitors:</p><p>In the treatment of class II-IV heart failure (NYHA) with an ejection fraction &lt;40%, and previously treated with ACE inhibitors and loop diuretics, risk of hyperkalaemia, potentially lethal, especially in case of non-observance of the prescription recommendations on this combination.</p><p>Before initiating the combination, check the absence of hyperkalaemia and renal impairment.</p><p>A close monitoring of the kalaemia and creatininemia is recommended in the first month of the treatment once a week at the beginning and, monthly thereafter.</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>indapamide</p></td><td style="vertical-align:top"><p>Torsades de pointes inducing drugs</p></td><td style="vertical-align:top"><p>Due to the risk of hypokalemia, indapamide should be administered with caution when associated with medicinal products that induced torsades de pointes such as but not limited to:</p><p>- class Ia antiarrhythmic agents (e.g.quinidine, hydroquinidine, disopyramide),</p><p>- class III antiarrhythmic agents (e.g.g amiodarone, dofetilide, ibutilide, bretylium, sotalol),</p><p>- some antipsychotics:</p><p>Phenothiazines (e.g. chlorpromazine, cyamemazine, levomepromazine, thioridazine, trifluoperazine),</p><p>benzamides (e.g. amisulpride, sulpiride, sultopride, tiapride),</p><p>butyrophenones (e.g. droperidol, haloperidol),</p><p>other antipsychotics (e.g. pimozide);</p><p>other substances (e.g. bepridil, cisapride, diphemanil, erythromycin IV, halofantrine, mizolastine, moxifloxacin, pentamidine, sparfloxacin,&nbsp; vincamine IV, methadone, astemizole, terfenadine).</p><p>Prevention of low potassium levels and correction if necessary : monitoring of the QT interval</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Amphotericin B (IV route), glucocorticoids and mineralocorticoids (systemic route), tetracosactide, stimulant laxatives</p></td><td style="vertical-align:top"><p>Increased risk of low potassium levels (additive effect). Monitoring of potassium levels, and correction if necessary; particular consideration required in cases of treatment with cardiac glycosides. Non stimulant laxatives should be used.</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Cardiac glycosides</p></td><td style="vertical-align:top"><p>Hypokalaemia and/or hypomagnesaemia predispose to the toxic effects of digitalis. Monitoring of plasma potassium, magnesium and ECG is recommended and, if necessary, adjusting the treatment.</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Allopurinol</p></td><td style="vertical-align:top"><p>Concomitant treatment with indapamide may increase the incidence of hypersensitivity reactions to allopurinol.</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>amlodipine</p></td><td style="vertical-align:top"><p>CYP3A4 inducers</p></td><td style="vertical-align:top"><p>Upon co-administration of known inducers of the CYP3A4, the plasma concentration of amlodipine may vary. Therefore, blood pressure should be monitored and dose regulation considered both during and after concomitant medication particularly with strong CYP3A4 inducers (e.g. rifampicin, hypericum perforatum).</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>CYP3A4 inhibitors</p></td><td style="vertical-align:top"><p>Concomitant use of amlodipine with strong or moderate CYP3A4 inhibitors (protease inhibitors, azole antifungals, macrolides like erythromycin or clarithromycin, verapamil or diltiazem) may give rise to significant increase in amlodipine exposure. The clinical translation of these PK variations may be more pronounced in the elderly. Clinical monitoring and dose adjustment may thus be required.</p><p>There is an increased risk of hypotension in patients receiving clarithromycin with amlodipine. Close observation of patients is recommended when amlodipine is co administered with clarithromycin.</p></td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p>&nbsp;</p><p><em>Concomitant use</em> <em>to be taken into consideration:</em></p><p><em>&nbsp;</em></p><table border="0" cellspacing="0" cellpadding="0"><thead><tr><td style="vertical-align:top"><p><strong><em>Component</em></strong></p></td><td style="vertical-align:top"><p><strong><em>Known interaction with the following product</em></strong></p></td><td style="vertical-align:top"><p><strong><em>Interaction with other medicinal product</em></strong></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p>perindopril / indapamide / amlodipine</p></td><td style="vertical-align:top"><p>Imipramine-like antidepressants (tricyclics), neuroleptics</p></td><td style="vertical-align:top"><p>Increased antihypertensive effect and increased risk of orthostatic hypotension (additive effect).</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>other antihypertensive agents</p></td><td style="vertical-align:top"><p>Use of other antihypertensive medicinal products could result in additional blood pressure lowering effect.</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Corticosteroids, tetracosactide</p></td><td style="vertical-align:top"><p>Reduction in antihypertensive effect (salt and water retention due to corticosteroids).</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>perindopril</p></td><td style="vertical-align:top"><p>Antihypertensive agents and</p><p>vasodilators</p></td><td style="vertical-align:top"><p>Concomitant use with nitroglycerin and other nitrates, or other vasodilators, may further reduce blood pressure</p></td></tr><tr><td style="vertical-align:top"><p>Allopurinol<em>, </em>cytostatic or immunosuppressive agents, systemic corticosteroids or procainamide</p></td><td style="vertical-align:top"><p>Concomitant administration with ACE inhibitors may lead to an increased risk for leucopenia.</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Anaesthetic drugs</p></td><td style="vertical-align:top"><p>ACE inhibitors may enhance the hypotensive effects of certain anaesthetic drugs</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Diuretics (thiazide or loop diuretics)</p></td><td style="vertical-align:top"><p>Prior treatment with high dose diuretics may result in volume depletion and in a risk of hypotension when initiating therapy with perindopril.</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Sympathomimetics</p></td><td style="vertical-align:top"><p>Sympathomimetics may reduce the antihypertensive effects of ACE inhibitors</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Gold</p></td><td style="vertical-align:top"><p>Nitritoid reactions (symptoms include facial flushing, nausea, vomiting and hypotension) have been reported rarely in patients on therapy with injectable gold (sodium aurothiomalate) and concomitant ACE inhibitor therapy including perindopril.</p></td></tr><tr><td style="vertical-align:top"><p>indapamide</p></td><td style="vertical-align:top"><p>Metformin</p></td><td style="vertical-align:top"><p>Lactic acidosis due to metformin caused by possible functional renal insufficiency linked to diuretics and in particular to loop diuretics. Do not use metformin when plasma creatinine levels exceed 15&nbsp;mg/l (135&nbsp;micromol/l) in men and 12&nbsp;mg/l (110&nbsp;micromol/l) in women.</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Iodinated contrast media</p></td><td style="vertical-align:top"><p>In cases of dehydration caused by diuretics, there is an increased risk of acute renal insufficiency, particularly when high doses of iodinated contrast media are used. Rehydration should be carried out before the iodinated compound is administered.</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Calcium (salts)</p></td><td style="vertical-align:top"><p>Risk of increased levels of calcium due to reduced elimination of calcium in the urine.</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Ciclosporin</p></td><td style="vertical-align:top"><p>Risk of increased creatinine levels with no change in circulating levels of ciclosporin, even when there is no salt and water depletion.</p></td></tr><tr><td rowspan="5" style="vertical-align:top"><p>amlodipine</p></td><td style="vertical-align:top"><p>Atorvastatin, digoxin or warfarin</p></td><td style="vertical-align:top"><p>In clinical interaction studies, amlodipine did not affect the pharmacokinetics of atorvastatin, digoxin or warfarin.</p></td></tr><tr><td style="vertical-align:top"><p>Tacrolimus</p></td><td style="vertical-align:top"><p>There is a risk of increased tacrolimus blood levels when co administered with amlodipine. In order to avoid toxicity of tacrolimus, administration of amlodipine in a patient treated with tacrolimus requires monitoring of tacrolimus blood levels and dose adjustment of tacrolimus when appropriate.</p></td></tr><tr><td style="vertical-align:top"><p>Mechanistic Target of Rapamycin (mTOR) Inhibitors</p></td><td style="vertical-align:top"><p>mTOR inhibitors such as sirolimus, temsirolimus, and everolimus are CYP3A substrates. Amlodipine is a weak CYP3A inhibitor. With concomitant use of mTOR inhibitors, amlodipine may increase exposure of mTOR inhibitors.</p></td></tr><tr><td style="vertical-align:top"><p>Ciclosporin</p></td><td style="vertical-align:top"><p>No drug interaction studies have been conducted with ciclosporin and amlodipine in healthy volunteers or other populations with the exception of renal transplant patients, where variable trough concentration increases (average 0% - 40%) of ciclosporin were observed. Consideration should be given to monitoring ciclosporin levels in renal transplant patients on amlodipine, and ciclosporin dose reductions should be made as necessary.</p></td></tr><tr><td style="vertical-align:top"><p>Simvastatin</p></td><td style="vertical-align:top"><p>Co-administration of multiple doses of 10 mg of amlodipine with 80 mg simvastatin resulted in a 77% increase in exposure to simvastatin compared to simvastatin alone. Limit the dose of simvastatin in patients on amlodipine to 20 mg daily.</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Given the effects of the individual components in this combination product on pregnancy and lactation,</p><p>Triplixam is not recommended during the first trimester of pregnancy. Triplixam is contraindicated during the second and third trimesters of pregnancy.</p><p>Triplixam is not recommended during lactation. A decision should therefore be made whether to discontinue nursing or to discontinue Triplixam taking account the importance of this therapy for the mother.</p><p>&nbsp;</p><p><u>Pregnancy</u></p><p><u>&nbsp;</u></p><p><em>Perindopril:</em></p><p><s>&nbsp;</s></p><p><strong>The use of ACE inhibitors</strong><strong> </strong><strong>is not recommended during the first trimester of pregnancy (see section 4.4). The use of ACE inhibitors</strong><strong> </strong><strong>is contra-indicated during the second and third trimesters of pregnancy (see sections 4.3 and 4.4).</strong></p><p>&nbsp;</p><p>Epidemiological evidence regarding the risk of teratogenicity following exposure to ACE inhibitors during the first trimester of pregnancy has not been conclusive ; however a small increase in risk cannot be excluded. Unless continued ACE inhibitor therapy is considered essential, patients planning pregnancy should be changed to alternative anti-hypertensive treatments which have an established safety profile for use in pregnancy. When pregnancy is diagnosed, treatment with ACE inhibitors should be stopped immediately, and, if appropriate, alternative therapy should be started.</p><p>Exposure to ACE inhibitor therapy during the second and third trimesters is known to induce human foetotoxicity (decreased renal function, oligohydramnios, skull ossification retardation) and neonatal toxicity (renal failure, hypotension, hyperkalaemia) (see section 5.3).</p><p>Should exposure to ACE inhibitors have occurred from the second trimester of pregnancy, ultrasound check of renal function and skull is recommended.</p><p>Infants whose mothers have taken ACE inhibitors should be closely observed for hypotension (see sections 4.3 and 4.4).</p><p>&nbsp;</p><p><em>Indapamide:</em></p><p>There are no or limited amount of data (less than 300 pregnancy outcomes) from the use of indapamide in pregnant women. Prolonged exposure to thiazide during the third trimester of pregnancy can reduce maternal plasma volume as well as uteroplacental blood flow, which may cause a feto-placental ischemia and growth retardation. Moreover, rare cases of hypoglycemia and thrombocytopenia in neonates have been reported following exposure near term.</p><p>Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity (see section 5.3).</p><p>&nbsp;</p><p><em>Amlodipine:</em></p><p>The safety of amlodipine in human pregnancy has not been established.</p><p>In animal studies, reproductive toxicity was observed at high doses (see section 5.3).</p><p><u>&nbsp;</u></p><p><u>Breastfeeding</u></p><p>&nbsp;</p><p>Triplixam is not recommended during lactation.</p><p>&nbsp;</p><p><em>Perindopril:</em></p><p>Because no information is available regarding the use of perindopril&nbsp; during breastfeeding, perindopril is not recommended and alternative treatments with better established safety profiles during breast-feeding are preferable, especially while nursing a newborn or preterm infant.</p><p><em>&nbsp;</em></p><p><em>Indapamide:</em></p><p>There is insufficient information on the excretion of indapamide/metabolites in human milk. Hypersensitivity to sulfonamide-derived medicines and hypokalaemia might occur. A risk to newborns/infants cannot be excluded.</p><p>Indapamide is closely related to thiazide diuretics which have been associated, during breast-feeding, with a decrease or even suppression of milk lactation.</p><p><em>&nbsp;</em></p><p><em>Amlodipine:</em></p><p>Amlodipine is excreted in human milk. The proportion of the maternal dose received by the infant has been estimated with an interquartile range of 3 &ndash; 7%, with a maximum of 15%. The effect of amlodipine on infants is unknown.</p><p><em><u>&nbsp;</u></em></p><p><u>Fertility</u></p><p>&nbsp;</p><p><em>Common to perindopril and indapamide:</em></p><p>Reproductive toxicity studies showed no effect on fertility in female and male rats (see section 5.3). No effects on human fertility are anticipated.</p><p>&nbsp;</p><p><em>Amlodipine:</em></p><p>Reversible biochemical changes in the head of spermatozoa have been reported in some patients treated by calcium channel blockers. Clinical data are insufficient regarding the potential effect of amlodipine on fertility. In one rat study, adverse effects were found on male fertility (see section 5.3).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No studies on the effects of Triplixam on the ability to drive and use machines have been performed.</p><p>Perindopril and indapamide have no influence on the ability to drive and use machines but individual reactions related to low blood pressure may occur in some patients.</p><p>Amlodipine can have minor or moderate influence on the ability to drive and use machines. If patients suffer from dizziness, headache, fatigue, weariness or nausea, the ability to react may be impaired.</p><p>As a result the ability to drive or operate machinery may be impaired. Caution is recommended especially at the start of treatment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile</u></p><p>The most commonly reported adverse reactions with perindopril, indapamide and amlodipine given separately are: hypokalaemia, dizziness, headache, paraesthesia, &nbsp;somnolence, dysgeusia, visual impairment, diplopia, tinnitus, vertigo, palpitations, flushing, hypotension (and effects related to hypotension), cough, dyspnoea, gastro-intestinal disorders (abdominal pain, constipation, diarrhoea, dyspepsia, nausea, vomiting, change of bowel habit), pruritus, rash, rash maculo-papular, muscle spasms, ankle swelling, asthenia, oedema and fatigue.</p><p>&nbsp;</p><p>&nbsp;</p><p><u>Tabulated list of adverse reactions</u></p><p>The following undesirable effects have been observed with perindopril, indapamide or amlodipine during treatment and ranked under the following frequency:</p><p>Very common (&sup3;1/10); common (&sup3;1/100 to &lt;1/10); uncommon (&sup3;1/1,000 to &lt;1/100); rare (&sup3;1/10,000 to &lt;1/1,000); very rare (&lt;1/10,000); not known (cannot be estimated from the available data).</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:99%"><tbody><tr><td rowspan="2"><p><strong>MedDRA</strong></p><p><strong>System Organ Class</strong></p></td><td rowspan="2"><p><strong>Undesirable Effects</strong></p></td><td colspan="3"><p><strong>Frequency</strong></p></td></tr></tbody><thead><tr><td><p><strong>Perindopril</strong></p></td><td><p><strong>Indapamide</strong></p></td><td><p><strong>Amlodipine</strong></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p><strong>Infections and infestations</strong></p></td><td><p>Rhinitis</p></td><td><p>Very rare</p></td><td><p>-</p></td><td><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p><strong>Endocrine disorders</strong></p></td><td style="vertical-align:top"><p>Syndrome of inappropriate antidiuretic hormone secretion (SIADH)</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>-</p></td><td><p>&nbsp;</p></td></tr><tr><td rowspan="8"><p><strong>Blood and Lymphatic System Disorders </strong></p></td><td><p>Eosinophilia</p></td><td><p>Uncommon*</p></td><td><p>-</p></td><td><p>-</p></td></tr><tr><td><p>Agranulocytosis (see section 4.4)</p></td><td><p>Very rare</p></td><td><p>Very rare</p></td><td><p>-</p></td></tr><tr><td><p>Aplastic anaemia</p></td><td><p>-</p></td><td><p>Very rare</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Pancytopenia</p></td><td><p>Very rare</p></td><td><p>-</p></td><td><p>-</p></td></tr><tr><td><p>Leukopenia (see section 4.4)</p></td><td><p>Very rare</p></td><td><p>Very rare</p></td><td><p>Very rare</p></td></tr><tr><td><p>Neutropenia (see section 4.4)</p></td><td><p>Very rare</p></td><td><p>-</p></td><td><p>-</p></td></tr><tr><td><p>Haemolytic anaemia</p></td><td><p>Very rare</p></td><td><p>Very rare</p></td><td><p>-</p></td></tr><tr><td><p>Thrombocytopenia (see section 4.4)</p></td><td><p>Very rare</p></td><td><p>Very rare</p></td><td><p>Very rare</p></td></tr><tr><td><p><strong>Immune System Disorders</strong></p></td><td><p>Hypersensitivity</p></td><td><p>-</p></td><td><p>Uncommon</p></td><td><p>Very rare</p></td></tr><tr><td rowspan="8"><p><strong>Metabolism and Nutrition Disorders</strong></p></td><td><p>Hypoglycaemia (see sections 4.4 and 4.5)</p></td><td><p>Uncommon*</p></td><td><p>-</p></td><td><p>-</p></td></tr><tr><td><p>Hyperkalaemia reversible on discontinuation (see section 4.4)</p></td><td><p>Uncommon*</p></td><td><p>-</p></td><td><p>-</p></td></tr><tr><td><p>Hyponatraemia (see section 4.4)</p></td><td><p>Uncommon*</p></td><td><p>Uncommon</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Hypochloraemia</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Rare</p></td><td><p>-</p></td></tr><tr><td style="vertical-align:top"><p>Hypomagnesaemia</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Rare</p></td><td><p>-</p></td></tr><tr><td><p>Hyperglycaemia</p></td><td><p>-</p></td><td><p>-</p></td><td><p>Very rare</p></td></tr><tr><td><p>Hypercalcaemia</p></td><td><p>-</p></td><td><p>Very rare</p></td><td><p>-</p></td></tr><tr><td><p>Hypokalaemia, (see section 4.4)</p></td><td><p>-</p></td><td><p>Common</p></td><td><p>-</p></td></tr><tr><td rowspan="5"><p><strong>Psychiatric disorders</strong></p></td><td><p>Insomnia</p></td><td><p>-</p></td><td><p>-</p></td><td><p>Uncommon</p></td></tr><tr><td><p>Mood altered (including anxiety)</p></td><td><p>Uncommon</p></td><td><p>-</p></td><td><p>Uncommon</p></td></tr><tr><td><p>Depression</p></td><td><p>Uncommon*</p></td><td><p>-</p></td><td><p>Uncommon</p></td></tr><tr><td><p>Sleep&nbsp; disorder</p></td><td><p>Uncommon</p></td><td><p>-</p></td><td><p>-</p></td></tr><tr><td><p>Confusional state</p></td><td><p>Very rare</p></td><td><p>-</p></td><td><p>Rare</p></td></tr><tr><td rowspan="13"><p><strong>Nervous System disorders</strong></p></td><td><p>Dizziness</p></td><td><p>Common</p></td><td><p>-</p></td><td><p>Common</p></td></tr><tr><td><p>Headache</p></td><td><p>Common</p></td><td><p>Rare</p></td><td><p>Common</p></td></tr><tr><td><p>Paraesthesia</p></td><td><p>Common</p></td><td><p>Rare</p></td><td><p>Uncommon</p></td></tr><tr><td><p>Somnolence</p></td><td><p>Uncommon*</p></td><td><p>-</p></td><td><p>Common</p></td></tr><tr><td><p>Hypoaesthesia</p></td><td><p>-</p></td><td><p>-</p></td><td><p>Uncommon</p></td></tr><tr><td><p>Dysgeusia</p></td><td><p>Common</p></td><td><p>-</p></td><td><p>Uncommon</p></td></tr><tr><td><p>Tremor</p></td><td><p>-</p></td><td><p>-</p></td><td><p>Uncommon</p></td></tr><tr><td><p>Syncope</p></td><td><p>Uncommon*</p></td><td><p>Not known</p></td><td><p>Uncommon</p></td></tr><tr><td><p>Hypertonia</p></td><td><p>-</p></td><td><p>-</p></td><td><p>Very rare</p></td></tr><tr><td><p>Neuropathy peripheral</p></td><td><p>-</p></td><td><p>-</p></td><td><p>Very rare</p></td></tr><tr><td><p>Extrapyramidal disorder (extrapyramidal syndrome)</p></td><td><p>-</p></td><td><p>-</p></td><td><p>Not known</p></td></tr><tr><td><p>Stroke possibly secondary to excessive hypotension in high-risk patients (see section 4.4)</p></td><td><p>Very rare</p></td><td><p>-</p></td><td><p>-</p></td></tr><tr><td><p>Possibility of onset of &nbsp;hepatic encephalopathy&nbsp; in case of hepatic insufficiency (see sections 4.3 and 4.4)</p></td><td><p>-</p></td><td><p>Not known</p></td><td><p>-</p></td></tr><tr><td rowspan="6"><p><strong>Eye Disorders </strong></p></td><td><p>Visual impairment</p></td><td><p>Common</p></td><td><p>Not known</p></td><td><p>Common</p></td></tr><tr><td><p>Acute angle-closure glaucoma</p></td><td><p>-</p></td><td><p>Not known</p></td><td><p>-</p></td></tr><tr><td><p>Choroidal effusion</p></td><td><p>-</p></td><td><p>Not known</p></td><td><p>-</p></td></tr><tr><td><p>Diplopia</p></td><td><p>-</p></td><td><p>-</p></td><td><p>Common</p></td></tr><tr><td><p>Myopia</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Not known</p></td><td><p>-</p></td></tr><tr><td><p>Vision blurred</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Not known</p></td><td><p>-</p></td></tr><tr><td rowspan="2"><p><strong>Ear and labyrinth disorders</strong></p></td><td><p>Tinnitus</p></td><td><p>Common</p></td><td><p>-</p></td><td><p>Uncommon</p></td></tr><tr><td><p>Vertigo</p></td><td><p>Common</p></td><td><p>Rare</p></td><td><p>-</p></td></tr><tr><td rowspan="6"><p><strong>Cardiac Disorders</strong></p></td><td><p>Palpitations</p></td><td><p>Uncommon*</p></td><td><p>-</p></td><td><p>Common</p></td></tr><tr><td><p>Tachycardia</p></td><td><p>Uncommon*</p></td><td><p>-</p></td><td><p>-</p></td></tr><tr><td><p>Angina pectoris (see section 4.4)</p></td><td><p>Very rare</p></td><td><p>-</p></td><td><p>-</p></td></tr><tr><td><p>Arrhythmia (including bradycardia, ventricular tachycardia and atrial fibrillation)</p></td><td><p>Very rare</p></td><td><p>Very rare</p></td><td><p>Uncommon</p></td></tr><tr><td><p>Myocardial infarction, possibly secondary to excessive hypotension in high risk patients (see section 4.4)</p></td><td><p>Very rare</p></td><td><p>-</p></td><td><p>Very rare</p></td></tr><tr><td><p>Torsade de pointes (potentially fatal) (see sections 4.4 and 4.5)</p></td><td><p>-</p></td><td><p>Not known</p></td><td><p>-</p></td></tr><tr><td rowspan="4"><p><strong>Vascular Disorders </strong></p></td><td><p>Flushing</p></td><td><p>Rare*</p></td><td><p>-</p></td><td><p>Common</p></td></tr><tr><td><p>Hypotension (and effects related to hypotension) (see section 4.4)</p></td><td><p>Common</p></td><td><p>Very rare</p></td><td><p>Uncommon</p></td></tr><tr><td><p>Vasculitis</p></td><td><p>Uncommon*</p></td><td><p>-</p></td><td><p>Very rare</p></td></tr><tr><td><p>Raynaud&rsquo;s phenomenon</p></td><td><p>Not known</p></td><td><p>-</p></td><td><p>-</p></td></tr><tr><td rowspan="4"><p><strong>Respiratory, Thoracic and Mediastinal Disorders </strong></p></td><td><p>Cough&nbsp; (see section 4.4)</p></td><td><p>Common</p></td><td><p>-</p></td><td><p>Uncommon</p></td></tr><tr><td><p>Dyspnoea</p></td><td><p>Common</p></td><td><p>-</p></td><td><p>Common</p></td></tr><tr><td><p>Bronchospasm</p></td><td><p>Uncommon</p></td><td><p>-</p></td><td><p>-</p></td></tr><tr><td><p>Eosinophilic pneumonia</p></td><td><p>Very rare</p></td><td><p>-</p></td><td><p>-</p></td></tr><tr><td rowspan="11"><p><strong>Gastro-intestinal Disorders</strong></p></td><td><p>Abdominal pain</p></td><td><p>Common</p></td><td><p>-</p></td><td><p>Common</p></td></tr><tr><td><p>Constipation</p></td><td><p>Common</p></td><td><p>Rare</p></td><td><p>Common</p></td></tr><tr><td><p>Diarrhoea</p></td><td><p>Common</p></td><td><p>-</p></td><td><p>Common</p></td></tr><tr><td><p>Dyspepsia</p></td><td><p>Common</p></td><td><p>-</p></td><td><p>Common</p></td></tr><tr><td><p>Nausea</p></td><td><p>Common</p></td><td><p>Rare</p></td><td><p>Common</p></td></tr><tr><td><p>Vomiting</p></td><td><p>Common</p></td><td><p>Uncommon</p></td><td><p>Uncommon</p></td></tr><tr><td><p>Dry mouth</p></td><td><p>Uncommon</p></td><td><p>Rare</p></td><td><p>Uncommon</p></td></tr><tr><td><p>Change of bowel habit</p></td><td><p>-</p></td><td><p>-</p></td><td><p>Common</p></td></tr><tr><td><p>Gingival hyperplasia</p></td><td><p>-</p></td><td><p>-</p></td><td><p>Very rare</p></td></tr><tr><td><p>Pancreatitis</p></td><td><p>Very rare</p></td><td><p>Very rare</p></td><td><p>Very rare</p></td></tr><tr><td><p>Gastritis</p></td><td><p>-</p></td><td><p>-</p></td><td><p>Very rare</p></td></tr><tr><td rowspan="3"><p><strong>Hepato-biliary Disorders</strong></p></td><td><p>Hepatitis (see section 4.4)</p></td><td><p>Very rare</p></td><td><p>Not known</p></td><td><p>Very rare</p></td></tr><tr><td><p>Jaundice</p></td><td><p>-</p></td><td><p>-</p></td><td><p>Very rare</p></td></tr><tr><td><p>Hepatic function abnormal</p></td><td><p>-</p></td><td><p>Very rare</p></td><td><p>-</p></td></tr><tr><td rowspan="18"><p><strong>Skin and Subcutaneous Tissue Disorders</strong></p></td><td><p>Pruritus</p></td><td><p>Common</p></td><td><p>-</p></td><td><p>Uncommon</p></td></tr><tr><td><p>Rash</p></td><td><p>Common</p></td><td><p>-</p></td><td><p>Uncommon</p></td></tr><tr><td><p>Rash maculo-papular</p></td><td><p>&nbsp;</p></td><td><p>Common</p></td><td><p>-</p></td></tr><tr><td><p>Urticaria (see section 4.4)</p></td><td><p>Uncommon</p></td><td><p>Very rare</p></td><td><p>Uncommon</p></td></tr><tr><td><p>Angioedema (see section 4.4)</p></td><td><p>Uncommon</p></td><td><p>Very rare</p></td><td><p>Very rare</p></td></tr><tr><td><p>Alopecia</p></td><td><p>-</p></td><td><p>-</p></td><td><p>Uncommon</p></td></tr><tr><td><p>Purpura</p></td><td><p>-</p></td><td><p>Uncommon</p></td><td><p>Uncommon</p></td></tr><tr><td><p>Skin discolouration</p></td><td><p>-</p></td><td><p>-</p></td><td><p>Uncommon</p></td></tr><tr><td><p>Hyperhidrosis</p></td><td><p>Uncommon</p></td><td><p>-</p></td><td><p>Uncommon</p></td></tr><tr><td><p>Exanthema</p></td><td><p>-</p></td><td><p>-</p></td><td><p>Uncommon</p></td></tr><tr><td><p>Photosensitivity reaction</p></td><td><p>Uncommon*</p></td><td><p>Not known</p><p>(see section 4.4)</p></td><td><p>Very rare</p></td></tr><tr><td><p>Psoriasis aggravation</p></td><td><p>Rare</p></td><td><p>-</p></td><td><p>-</p></td></tr><tr><td><p>Pemphigoid</p></td><td><p>Uncommon*</p></td><td><p>-</p></td><td><p>-</p></td></tr><tr><td><p>Erythema multiforme</p></td><td><p>Very rare</p></td><td><p>-</p></td><td><p>Very rare</p></td></tr><tr><td><p>Stevens-Johnson Syndrome</p></td><td><p>-</p></td><td><p>Very rare</p></td><td><p>Very rare</p></td></tr><tr><td><p>Exfoliative dermatitis</p></td><td><p>-</p></td><td><p>-</p></td><td><p>Very rare</p></td></tr><tr><td><p>Toxic epidermal necrolysis</p></td><td><p>-</p></td><td><p>Very rare</p></td><td><p>Not known</p></td></tr><tr><td><p>Quincke&rsquo;s oedema</p></td><td><p>-</p></td><td><p>-</p></td><td><p>Very rare</p></td></tr><tr><td rowspan="8"><p><strong>Musculoskeletal&nbsp; And Connective Tissue Disorders</strong></p></td><td><p>Muscle spasms</p></td><td><p>Common</p></td><td><p>Not known</p></td><td><p>Common</p></td></tr><tr><td><p>Ankle swelling</p></td><td><p>-</p></td><td><p>-</p></td><td><p>Common</p></td></tr><tr><td><p>Arthralgia</p></td><td><p>Uncommon *</p></td><td><p>-</p></td><td><p>Uncommon</p></td></tr><tr><td><p>Muscular weakness</p></td><td><p>-</p></td><td><p>Not known</p></td><td><p><strong>-</strong></p></td></tr><tr><td><p>Myalgia</p></td><td><p>Uncommon *</p></td><td><p>Not known</p></td><td><p>Uncommon</p></td></tr><tr><td><p>Rhabdomyolysis</p></td><td><p>-</p></td><td><p>Not known</p></td><td><p><strong>-</strong></p></td></tr><tr><td><p>Back pain</p></td><td><p>-</p></td><td><p>-</p></td><td><p>Uncommon</p></td></tr><tr><td><p>Possible worsening of pre-existing systemic&nbsp; lupus erythematosus</p></td><td><p>-</p></td><td><p>Not known</p></td><td><p>-</p></td></tr><tr><td rowspan="6"><p><strong>Renal and Urinary Disorders</strong></p></td><td><p>Micturition disorder</p></td><td><p>-</p></td><td><p>-</p></td><td><p>Uncommon</p></td></tr><tr><td><p>Nocturia</p></td><td><p>-</p></td><td><p>-</p></td><td><p>Uncommon</p></td></tr><tr><td><p>Pollakiuria</p></td><td><p>-</p></td><td><p>-</p></td><td><p>Uncommon</p></td></tr><tr><td><p>Anuria/oliguria</p></td><td><p>Rare*</p></td><td><p>-</p></td><td><p>-</p></td></tr><tr><td><p>Acute renal failure</p></td><td><p>Rare</p></td><td><p>-</p></td><td><p>-</p></td></tr><tr><td><p>Renal failure</p></td><td><p>Uncommon</p></td><td><p>Very rare</p></td><td><p>-</p></td></tr><tr><td rowspan="2"><p><strong>Reproductive System and Breast Disorders</strong></p></td><td><p>Erectile dysfunction</p></td><td><p>Uncommon</p></td><td><p>Uncommon</p></td><td><p>Uncommon</p></td></tr><tr><td><p>Gynaecomastia</p></td><td><p>-</p></td><td><p>-</p></td><td><p>Uncommon</p></td></tr><tr><td rowspan="8"><p><strong>General Disorders and Administration Site Conditions </strong></p><p><strong>&nbsp;</strong></p></td><td><p>Asthenia</p></td><td><p>Common</p></td><td><p>-</p></td><td><p>Common</p></td></tr><tr><td><p>Fatigue</p></td><td><p>-</p></td><td><p>Rare</p></td><td><p>Common</p></td></tr><tr><td><p>Oedema</p></td><td><p>-</p></td><td><p>-</p></td><td><p>Very common</p></td></tr><tr><td><p>Chest pain</p></td><td><p>Uncommon*</p></td><td><p>-</p></td><td><p>Uncommon</p></td></tr><tr><td><p>Pain</p></td><td><p>-</p></td><td><p>-</p></td><td><p>Uncommon</p></td></tr><tr><td><p>Malaise</p></td><td><p>Uncommon*</p></td><td><p>-</p></td><td><p>Uncommon</p></td></tr><tr><td><p>Oedema peripheral</p></td><td><p>Uncommon*</p></td><td><p>-</p></td><td><p>-</p></td></tr><tr><td><p>Pyrexia</p></td><td><p>&nbsp;Uncommon*</p></td><td><p>-</p></td><td><p>-</p></td></tr><tr><td rowspan="10"><p><strong>Investigations</strong></p></td><td><p>Weight increased</p></td><td><p>-</p></td><td><p>-</p></td><td><p>Uncommon</p></td></tr><tr><td><p>Weight decreased</p></td><td><p>-</p></td><td><p>-</p></td><td><p>Uncommon</p></td></tr><tr><td><p>Blood urea increased</p></td><td><p>Uncommon*</p></td><td><p>-</p></td><td><p>-</p></td></tr><tr><td><p>Blood creatinine increased</p></td><td><p>Uncommon*</p></td><td><p>-</p></td><td><p>-</p></td></tr><tr><td><p>Blood bilirubin increased</p></td><td><p>Rare</p></td><td><p>-</p></td><td><p>-</p></td></tr><tr><td><p>Hepatic enzyme increased</p></td><td><p>Rare</p></td><td><p>Not known</p></td><td><p>Very rare</p></td></tr><tr><td><p>Haemoglobin&nbsp; decreased and haematocrit decreased (see section 4.4)</p></td><td><p>Very rare</p></td><td><p>-</p></td><td><p>-</p></td></tr><tr><td><p>Electrocardiogram QT prolonged (see sections 4.4 and 4.5)</p></td><td><p>-</p></td><td><p>Not known</p></td><td><p>-</p></td></tr><tr><td><p>Blood glucose increased</p></td><td><p>-</p></td><td><p>Not known</p></td><td><p>-</p></td></tr><tr><td><p>Blood uric acid increased</p></td><td><p>-</p></td><td><p>Not known</p></td><td><p>-</p></td></tr><tr><td><p><strong>Injury, poisoning and procedural complications</strong></p></td><td><p>Fall</p></td><td><p>Uncommon *</p></td><td><p>-</p></td><td><p>-</p></td></tr></tbody></table><p><em>* Frequency calculated from clinical trials for adverse events detected from spontaneous report</em></p><p><u>&nbsp;</u></p><p>&nbsp;</p><p>Description of selected adverse reactions:</p><p>During phase II and III studies comparing indapamide 1.5mg and 2.5mg, plasma potassium analysis showed a dose-dependent effect of indapamide:</p><p>- Indapamide 1.5mg: Plasma potassium &lt;3.4 mmol/l was seen in 10 % of patients and &lt; 3.2 mmol/l in 4 % of patients after 4 to 6 weeks treatment. After 12 weeks treatment, the mean fall in plasma potassium was 0.23 mmol/l.</p><p>- Indapamide 2.5 mg: Plasma potassium &lt;3.4 mmol/l was seen in 25 % of patients and &lt; 3.2 mmol/l in 10 % of patients after 4 to 6 weeks treatment. After 12 weeks treatment, the mean fall in plasma potassium was 0.41 mmol/l.</p><p>&nbsp;</p><p><u>&nbsp;</u></p><p><u>Reporting of suspected adverse reactions</u></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There is no information on overdosage with Triplixam in humans.</p><p>&nbsp;</p><p><em>For perindopril/indapamide combination</em></p><p>Symptoms</p><p>Tthe most likely adverse reaction in cases of overdose is hypotension, sometimes associated with nausea, vomiting, cramps, dizziness, sleepiness, mental confusion, oliguria which may progress to anuria (due to hypovolaemia). Salt and water disturbances (low sodium levels, low potassium levels) may occur.</p><p>&nbsp;</p><p>Management</p><p>The first measures to be taken consist of rapidly eliminating the product(s) ingested by gastric lavage and/or administration of activated charcoal, then restoring fluid and electrolyte balance in a specialised centre until they return to normal.</p><p>If marked hypotension occurs, this can be treated by placing the patient in a supine position with the head lowered. If necessary an intravenous<strong><em> </em></strong>infusion of isotonic saline may be given, or any other method of volaemic expansion may be used.</p><p>Perindoprilat, the active form of perindopril, can be dialysed (see section 5.2).</p><p>&nbsp;</p><p><em>For amlodipine</em>,</p><p>Experience with intentional overdose in humans is limited.</p><p>Symptoms</p><p>Available data suggest that gross overdosage could result in excessive peripheral vasodilatation and possibly reflex tachycardia. Marked and probably prolonged systemic hypotension up to and including shock with fatal outcome have been reported.</p><p>Non-cardiogenic pulmonary oedema has rarely been reported as a consequence of amlodipine overdose that may manifest with a delayed onset (24-48 hours post-ingestion) and require ventilatory support. Early resuscitative measures (including fluid overload) to maintain perfusion and cardiac output may be precipitating factors.</p><p>&nbsp;</p><p>Management</p><p>Clinically significant hypotension due to amlodipine overdosage calls for active cardiovascular support including frequent monitoring of cardiac and respiratory function, elevation of extremities and attention to circulating fluid volume and urine output.</p><p>A vasoconstrictor may be helpful in restoring vascular tone and blood pressure, provided that there is no contraindication to its use. Intravenous calcium gluconate may be beneficial in reversing the effects of calcium channel blockade.</p><p>Gastric lavage may be worthwhile in some cases. In healthy volunteers the use of charcoal up to 2 hours after administration of amlodipine 10 mg has been shown to reduce the absorption rate of amlodipine.</p><p>Since amlodipine is highly protein-bound, dialysis is not likely to be of benefit.</p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;</p><p>Pharmacotherapeutic group: &nbsp;&nbsp;ACE inhibitors, combinations. ACE inhibitors, calcium channel blockers and diuretics. ATC code: C09BX01</p><p>Triplixam is a combination of three antihypertensive components with complementary mechanisms to control blood pressure in patient with hypertension. Perindopril arginine salt is an angiotensin converting enzyme inhibitor, indapamide, a chlorosulphamoyl diuretic and amlodipine, a calcium ion flux inhibitor of the dihydropyridine group.</p><p>The pharmacological properties of Triplixam are derived from those of each of the components taken separately. In addition, the combination of perindopril/ indapamide produces an additive synergy of the antihypertensive effects of the two components.</p><p>&nbsp;</p><p><u>Mechanism of action</u></p><p>&nbsp;</p><p><em>Perindopril:</em></p><p>Perindopril is an inhibitor of the angiotensin converting enzyme (ACE inhibitor) which converts angiotensin I to angiotensin II, a vasoconstricting substance; in addition the enzyme stimulates the secretion of aldosterone by the adrenal cortex and stimulates the degradation of bradykinin, a vasodilatory substance, into inactive heptapeptides.</p><p>&nbsp;</p><p>This results in:</p><p>-&nbsp;&nbsp;&nbsp; a reduction in aldosterone secretion,</p><p>-&nbsp;&nbsp;&nbsp; an increase in plasma renin activity, since aldosterone no longer exercises negative feedback,</p><p>-&nbsp;&nbsp;&nbsp; a reduction in total peripheral resistance with a preferential action on the vascular bed in muscle and the kidney, with no accompanying salt and water retention or reflex tachycardia, with chronic treatment.</p><p>&nbsp;</p><p>The antihypertensive action of perindopril also occurs in patients with low or normal renin concentrations.</p><p>&nbsp;</p><p>Perindopril acts through its active metabolite, perindoprilat. The other metabolites are inactive.</p><p>&nbsp;</p><p>Perindopril reduces the work of the heart:</p><p>-&nbsp;&nbsp;&nbsp; by a vasodilatory effect on veins, probably caused by changes in the metabolism of prostaglandins : reduction in pre-load,</p><p>-&nbsp;&nbsp;&nbsp; by reduction of the total peripheral resistance: reduction in afterload.</p><p>&nbsp;</p><p>Studies carried out on patients with cardiac insufficiency have shown:</p><p>-&nbsp;&nbsp;&nbsp; a reduction in left and right ventricular filling pressures,</p><p>-&nbsp;&nbsp;&nbsp; a reduction in total peripheral vascular resistance,</p><p>-&nbsp;&nbsp;&nbsp; an increase in cardiac output and an improvement in the cardiac index,</p><p>-&nbsp;&nbsp;&nbsp; an increase in regional blood flow in muscle.</p><p>Exercise test results also showed improvement.</p><p>&nbsp;</p><p><em>Indapamide:</em></p><p>Indapamide is a sulfonamide derivative with an indole ring, pharmacologically related to the thiazide group of diuretics. Indapamide inhibits the reabsorption of sodium in the cortical dilution segment. It increases the urinary excretion of sodium and chlorides and, to a lesser extent, the excretion of potassium and magnesium, thereby increasing urine output and having an antihypertensive action.</p><p>&nbsp;</p><p><em>Amlodipine:</em></p><p>Amlodipine is a calcium ion influx inhibitor of the dihydropyridine group (slow channel blocker or calcium ion antagonist) and inhibits the transmembrane influx of calcium ions into cardiac and vascular smooth muscle.</p><p><u>&nbsp;</u></p><p><u>Pharmacodynamic effects</u></p><p>&nbsp;</p><p><em>Perindopril/indapamide</em><em>:</em></p><p>In hypertensive patients regardless of age, the perindopril/indapamide combination exerts a dose-dependent antihypertensive effect on diastolic and systolic arterial pressure whilst supine or standing. During clinical trials, the concomitant administration of perindopril and indapamide produced antihypertensive effects of a synergic nature in relation to each of the products administered alone.</p><p>&nbsp;</p><p><em>Perindopril:</em></p><p>Perindopril is active in all grades of hypertension: mild to moderate or severe. A reduction in systolic and diastolic arterial pressure is observed in the lying and standing position.</p><p>The antihypertensive activity after a single dose is maximal at between 4 and 6 hours and is maintained over 24 hours.</p><p>There is a high degree of residual blocking of angiotensin converting enzyme at 24 hours, approximately&nbsp;80%.</p><p>In patients who respond, normalised blood pressure is reached after one month and is maintained without tachyphylaxis.</p><p>Withdrawal of treatment has no rebound effect on hypertension.</p><p>Perindopril has vasodilatory properties and restores elasticity of the main arterial trunks, corrects histomorphometric changes in resistance arteries and produces a reduction in left ventricular hypertrophy.</p><p>If necessary, the addition of a thiazide diuretic leads to an additive synergy.</p><p>The combination of an angiotensin converting enzyme inhibitor with a thiazide diuretic decreases the hypokalaemia risk associated with the diuretic alone.</p><p>&nbsp;</p><p><em>Indapamide:</em></p><p>Indapamide, as monotherapy, has an antihypertensive effect which lasts for 24&nbsp;hours. This effect occurs at doses at which the diuretic properties are minimal.</p><p>Its antihypertensive action is proportional to an improvement in arterial compliance and a reduction in total and arteriolar peripheral vascular resistance.</p><p>Indapamide reduces left ventricular hypertrophy.</p><p>When a dose of thiazide diuretic and thiazide-related diuretics is exceeded, the antihypertensive effect reaches a plateau, whereas the adverse effects continue to increase. If the treatment is ineffective, the dose should not be increased.</p><p>Furthermore, it has been shown that in the short-term, mid-term and long-term in hypertensive patients, indapamide:</p><p>-&nbsp;&nbsp;&nbsp; has no effect on lipid metabolism: triglycerides, LDL-cholesterol and HDL-cholesterol,</p><p>-&nbsp;&nbsp;&nbsp; has no effect on carbohydrate metabolism, even in diabetic hypertensive patients.</p><p>&nbsp;</p><p><em>Amlodipine:</em></p><p>The mechanism of the antihypertensive action of amlodipine is due to a direct relaxant effect on vascular smooth muscle. The precise mechanism by which amlodipine relieves angina has not been fully determined but amlodipine reduces total ischaemic burden by the following two actions:</p><p>&nbsp;</p><p>Amlodipine dilates peripheral arterioles and thus, reduces the total peripheral resistance (afterload) against which the heart works. Since the heart rate remains stable, this unloading of the heart reduces myocardial energy consumption and oxygen requirements.</p><p>&nbsp;</p><p>The mechanism of action of amlodipine also probably involves dilatation of the main coronary arteries and coronary arterioles, both in normal and ischaemic regions. This dilatation increases myocardial oxygen delivery in patients with coronary artery spasm (Prinzmetal&#39;s or variant angina).</p><p>&nbsp;</p><p>In patients with hypertension, once daily dosing provides clinically significant reductions of blood pressure in both the supine and standing positions throughout the 24 hour interval. Due to the slow onset of action, acute hypotension is not a feature of amlodipine administration.</p><p>Amlodipine has not been associated with any adverse metabolic effects or changes in plasma lipids and is suitable for use in patients with asthma, diabetes, and gout.</p><p><u>&nbsp;</u></p><p><u>Clinical efficacy and safety</u></p><p>&nbsp;</p><p>Triplixam has not been studied on morbidity and mortality.</p><p>&nbsp;</p><p><em>Perindopril/indapamide:</em></p><p>PICXEL, a multicenter, randomised, double blind active controlled study has assessed on echocardiography the effect of perindopril/indapamide combination on LVH versus enalapril monotherapy.</p><p>In PICXEL, hypertensive patients with LVH (defined as left ventricular mass index (LVMI) &gt; 120 g/m<sup>2</sup> in male and &gt; 100 g/m<sup>2</sup> in female) were randomised either to perindopril tert-butylamine 2 mg (equivalent to 2.5 mg perindopril arginine)/indapamide 0.625 mg or to enalapril 10 mg once a day for a one-year treatment. The dose was adapted according to blood pressure control, up to perindopril tert-butylamine 8 mg (equivalent to 10 mg perindopril arginine) and indapamide 2.5 mg or enalapril 40 mg once a day. Only 34% of the subjects remained treated with perindopril tert-butylamine 2 mg (equivalent to 2.5 mg perindopril arginine)/indapamide 0.625mg (versus 20% with enalapril 10mg).</p><p>At the end of treatment, LVMI had decreased significantly more in the perindopril/indapamide group (-10.1 g/m&sup2;) than in the enalapril group (-1.1 g/m&sup2;) in the all randomised patients population. The between group difference in LVMI change was -8.3 (95% CI (-11.5,-5.0), p &lt; 0.0001).</p><p>A better effect on LVMI was reached with higher perindopril/indapamide doses than those licensed for perindopril/indapamide 2.5mg/0.625mg and perindopril/indapamide 5mg/1.25mg.</p><p>Regarding blood pressure, the estimated mean between-group differences in the randomised population were -5.8 mmHg (95% CI (-7.9, -3.7), p &lt; 0.0001) for systolic blood pressure and -2.3 mmHg (95% CI (-3.6,-0.9), p = 0.0004) for diastolic blood pressure respectively, in favour of the perindopril/indapamide group.</p><p>&nbsp;</p><p>The ADVANCE study was a multicentre, international, randomised,&nbsp;2x2 factorial designed trial&nbsp;aimed at determining&nbsp; the benefits of Blood Pressure lowering with the fixed combination perindopril / indapamide vs placebo on top of current standard therapy (double blind comparison) and of gliclazide MR based intensive glucose control strategy (HbA1c target of 6.5% or lower) vs standard glucose control (PROBE [Prospective Randomised Open study with Blinded Evaluation] design) on major macrovascular and microvascular events in type 2 diabetic patients.</p><p>The primary end-point was a composite of major macrovascular (cardiovascular death, non-fatal myocardial infarction, non-fatal stroke) and microvascular (new or worsening nephropathy and eye disease) events.</p><p>Overall, 11 140 type 2 diabetic patients (mean values: age 66 years, BMI 28 kg/m<sup>2</sup>, duration of diabetes 8 years, HbA1c 7.5% and SBP/DBP 145/81 mmHg) were involved in the trial. Among them, 83% were hypertensive, 32% and 10% presented a history of macro- or micro- vascular disease respectively and 27% had microalbuminuria. Concomitant therapies included BP lowering agents (75%), lipid lowering agents (35% mainly statins 28%), aspirin or other antiplatelets (47%).</p><p>Following a 6-week run-in period on open perindopril / indapamide combination and usual glucose lowering treatment, patients were randomly assigned to placebo (n=5571) or perindopril / indapamide combination (n=5569).</p><p>After a mean duration of follow-up of 4.3 years, the treatment with perindopril / indapamide resulted in a significant relative risk reduction of 9 % in the primary endpoint (95%CI [0.828;0.996], p=0.041).</p><p>This benefit was driven by a significant relative risk reduction of 14 % in total mortality (95%CI [0.75;0.98], p=0.025), of 18% in cardiovascular deaths (95%CI [0.68;0.98], p=0.027) and of 21% in total renal events (95%CI [0.74;0.86], p&lt;0.001) in the perindopril / indapamide group compared to the placebo group.</p><p>In the sub-group of interest of hypertensive patients, there was a relative risk reduction of 9 % in the combined major macrovascular and microvascular events in the perindopril / indapamide group compared to the placebo group (95%CI [0.82;1.00], p=0.052).</p><p>There were also a significant relative risk reduction of 16 % in total mortality (95%CI [0.73;0.97], p=0.019), of 20 % in cardiovascular deaths (95%CI [0.66;0.97], p=0.023) and of 20 % in total renal events (95%CI [0.73;0.87], p&lt;0.001) in the perindopril / indapamide group compared to the placebo group.</p><p>The benefits of the BP lowering intervention were independent of those observed with the intensive glucose control strategy.</p><p><em>&nbsp;</em></p><p><em>Amlodipine:</em></p><p>A randomized double-blind morbidity-mortality study called the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) was performed to compare newer drug therapies: amlodipine 2.5-10 mg/d (calcium channel blocker) or lisinopril 10-40 mg/d (ACE-inhibitor) as first-line therapies to that of the thiazide-diuretic, chlorthalidone 12.5-25 mg/d in mild to moderate hypertension.&rdquo;</p><p>A total of 33,357 hypertensive patients aged 55 or older were randomized and followed for a mean of 4.9 years. The patients had at least one additional CHD risk factor, including: previous myocardial infarction or stroke (&gt; 6 months prior to enrollment) or documentation of other atherosclerotic CVD (overall 51.5%), type 2 diabetes (36.1%), HDL-C &lt; 35 mg/dL (11.6%), left ventricular hypertrophy diagnosed by electrocardiogram or echocardiography (20.9%), current cigarette smoking (21.9%).</p><p>The primary endpoint was a composite of fatal CHD or non-fatal myocardial infarction. There was no significant difference in the primary endpoint between amlodipine-based therapy and chlorthalidone-based therapy: RR 0.98 (95% CI (0.90-1.07) p=0.65. Among secondary endpoints, the incidence of heart failure (component of a composite combined cardiovascular endpoint) was significantly higher in the amlodipine group as compared to the chlorthalidone group (10.2% vs. 7.7%, RR 1.38, (95% CI [1.25-1.52] p&lt;0.001)). However, there was no significant difference in all-cause mortality between amlodipine-based therapy and chlorthalidone-based therapy. RR 0.96 (95% CI [0.89-1.02] p=0.20).</p><p>&nbsp;</p><p><em>Dual blockade of the renin-angiotensin-aldosterone system (RAAS) clinical trial data:</em></p><p>Two large randomised, controlled trials (ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial) and VA NEPHRON-D (The Veterans Affairs Nephropathy in Diabetes)) have examined the use of combination of an ACE-inhibitor with an angiotensin II receptor blocker.</p><p>ONTARGET was a study conducted in patients with a history of cardiovascular or cerebrovascular disease, or type 2 diabetes mellitus accompanied by evidence of end-organ damage. VA NEPHRON-D was a study in patients with type 2 diabetes mellitus and diabetic nephropathy.</p><p>These studies have shown no significant beneficial effect on renal and/or cardiovascular outcomes and mortality, while an increased risk of hyperkalaemia, acute kidney injury and/or hypotension as compared to monotherapy was observed.</p><p>Given their similar pharmacodynamic properties, these results are also relevant for other ACE-inhibitors and angiotensin II receptor blockers.</p><p>&nbsp;</p><p>ACE-inhibitors and angiotensin II receptor blockers should therefore not be used concomitantly in patients with diabetic nephropathy.</p><p>&nbsp;</p><p>ALTITUDE (Aliskiren Trial in Type 2 Diabetes Using Cardiovascular and Renal Disease Endpoints) was a study designed to test the benefit of adding aliskiren to a standard therapy of an ACE-inhibitor or an angiotensin II receptor blocker in patients with type 2 diabetes mellitus and chronic kidney disease, cardiovascular disease, or both. The study was terminated early because of an increased risk of adverse outcomes. Cardiovascular death and stroke were both numerically more frequent in the aliskiren group than in the placebo group and adverse events and serious adverse events of interest (hyperkalaemia, hypotension and renal dysfunction) were more frequently reported in the aliskiren group than in the placebo group.</p><p>&nbsp;</p><p><em>&nbsp;</em></p><p><em>Paediatric population:</em></p><p>No data are available with Triplixam in children.</p><p>The European Medicines Agency has waived the obligation to submit the results of studies with Triplixam in all subsets of the paediatric population in hypertension (see section 4.2 for information on paediatric use).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>Triplixam:</em></p><p>The co-administration of perindopril/indapamide and amlodipine does not change their pharmacokinetic properties by comparison to separate administration.</p><p>&nbsp;</p><p><em>Perindopril:</em></p><p><em>&nbsp;</em></p><p><u>Absorption and bioavailability</u></p><p>After oral administration, the absorption of perindopril is rapid and the peak concentration is achieved within 1 hour (perindopril is a prodrug and perindoprilat the active metabolite). The plasma half-life of perindopril is equal to 1 hour. As ingestion of food decreases conversion to perindoprilat, hence bioavailability, perindopril arginine should be administered orally in a single daily dose in the morning before a meal.</p><p>&nbsp;</p><p><u>Distribution</u></p><p>The volume of distribution is approximately 0.2 L/kg for unbound perindoprilat. Protein binding of perindoprilat to plasma proteins is 20%, principally to angiotensin converting enzyme, but is concentration-dependent.</p><p>&nbsp;</p><p><u>Biotransformation</u></p><p>Perindopril is a prodrug. Twenty seven percent of the administered perindopril dose reaches the bloodstream as the active metabolite perindoprilat. In addition to active perindoprilat, perindopril yields five metabolites, all inactive. The peak plasma concentration of perindoprilat is achieved within 3 to 4 hours.</p><p>&nbsp;</p><p><u>Elimination</u></p><p>Perindoprilat is eliminated in the urine and the terminal half-life of the unbound fraction is approximately 17 hours, resulting in steady-state within 4 days.</p><p>&nbsp;</p><p><u>Linearity/non-linearity</u></p><p>It has been demonstrated a linear relationship between the dose of perindopril and its plasma exposure.</p><p><u>&nbsp;</u></p><p><u>Special Populations</u></p><p>- <em>&nbsp;</em><em>Elderly</em><em>:</em> Elimination of perindoprilat is decreased in the elderly, and also in patients with heart or renal failure.</p><p>- <em>Renal impairment</em>: Dosage adjustment in renal insufficiency is desirable depending on the degree of impairment (creatinine clearance).</p><p>- <em>In case of dialysis</em>: clearance of perindoprilat is equal to 70 mL/min.</p><p>- <em>In patients with cirrhosis</em>: Perindopril pharmacokinetics is modified, hepatic clearance of the parent molecule is reduced by half. However, the quantity of perindoprilat formed is not reduced and therefore no dosage adjustment is required (see sections 4.2 and 4.4).</p><p>&nbsp;</p><p><em>Indapamide:</em></p><p>&nbsp;</p><p><u>Absorption</u></p><p>Indapamide is rapidly and completely absorbed from the digestive tract.</p><p>The peak plasma level is reached in humans approximately one hour after oral administration of the product.</p><p>&nbsp;</p><p><u>Distribution</u></p><p>Plasma protein binding is 79 %.</p><p><u>&nbsp;</u></p><p><u>Metabolism and Elimination</u></p><p>The elimination half-life is between 14 and 24 hours (average 18 hours). Repeated administration does not produce accumulation.</p><p>Elimination is mainly in the urine (70 % of the dose) and faeces (22&nbsp;%) in the form of inactive metabolites.</p><p>&nbsp;</p><p><u>Special populations</u></p><p>The pharmacokinetics is unchanged in patients with renal insufficiency.</p><p><em>&nbsp;</em></p><p><em>Amlodipine:</em></p><p><u>&nbsp;</u></p><p><u>Absorption and Bioavailability</u></p><p>After oral administration of therapeutic doses, amlodipine is well absorbed with peak blood levels between 6-12 hours post dose. Absolute bioavailability has been estimated to be between 64 and 80%.</p><p>The bioavailability of amlodipine is not affected by food intake.</p><p><u>&nbsp;</u></p><p><u>Distribution</u></p><p>The volume of distribution is approximately 21 L/kg. <em>In vitro</em> studies have shown that approximately 97.5% of circulating amlodipine is bound to plasma proteins.</p><p><u>&nbsp;</u></p><p><u>Metabolism</u></p><p>Amlodipine is extensively metabolised by the liver to inactive metabolites with 10% of the parent compound and 60% of metabolites excreted in the urine.</p><p><u>&nbsp;</u></p><p><u>Elimination</u></p><p>The terminal plasma elimination half-life is about 35-50 hours and is consistent with once daily dosing.</p><p>&nbsp;</p><p><u>Special populations</u></p><p>-&nbsp; Use in the elderly: the time to reach peak plasma concentrations of amlodipine is similar in elderly and younger subjects. Amlodipine clearance tends to be decreased with resulting increases in AUC and elimination half-life in elderly patients. Increases in AUC and elimination half-life in patients with congestive heart failure were as expected for the patient age group studied.</p><p>-&nbsp; Use in patients with impaired hepatic function: Very limited clinical data are available regarding amlodipine administration in patients with hepatic impairment. Patients with hepatic insufficiency have decreased clearance of amlodipine resulting in a longer half-life and an increase in AUC of approximately 40-60%.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>Perindopril:</em></p><p>In the chronic oral toxicity studies (rats and monkeys), the target organ is the kidney, with reversible damage.</p><p>No mutagenicity has been observed in in vitro or in vivo studies.</p><p>Reproduction toxicology studies (rats, mice, rabbits and monkeys) showed no sign of embryotoxicity or teratogenicity. However, angiotensin converting enzyme inhibitors, as a class, have been shown to induce adverse effects on late fetal development, resulting in fetal death and congenital effects in rodents and rabbits: renal lesions and an increase in peri- and postnatal mortality have been observed. Fertility was not impaired either in male or in female rats.</p><p>No carcinogenicity has been observed in long term studies in rats and mice.</p><p>&nbsp;</p><p>Indapamide:</p><p>The highest doses administered orally to different animal species (40 to 8000 times the therapeutic dose) have shown an exacerbation of the diuretic properties of indapamide. The major symptoms of poisoning during acute toxicity studies with indapamide administered intravenously or intraperitoneally were related to the pharmacological action of indapamide, <em>i.e</em>. bradypnoea and peripheral vasodilation.</p><p>Indapamide has been tested negative concerning mutagenic and carcinogenic properties.</p><p>Reproductive toxicity studies have not shown any embryotoxic or teratogenic effect in rat, mice and rabbit.</p><p>Fertility was not impaired either in male or female rats.</p><p>&nbsp;</p><p>Perindopril/indapamide:</p><p>The perindopril/indapamide combination has slightly increased toxicity than that of its components. Renal manifestations do not seem to be potentiated in the rat. However, the combination produces gastro-intestinal toxicity in the dog and the toxic effects on the mother seem to be increased in the rat (compared to perindopril).</p><p>Nonetheless, these adverse effects appear at dose levels corresponding to a very marked safety margin by comparison to the therapeutic doses used.</p><p>Preclinical studies performed separately with perindopril and indapamide did not show genotoxic, carcinogenic or teratogenic potential.</p><p>&nbsp;</p><p>Amlodipine:</p><p>Reproductive studies in rats and mice have shown delayed date of delivery, prolonged duration of labour and decreased pup survival at dosages approximately 50 times greater than the maximum recommended dosage for humans based on mg/kg.</p><p>There was no effect on the fertility of rats treated with amlodipine (males for 64 days and females 14 days prior to mating) at doses up to 10 mg/kg/day (8 times* the maximum recommended human dose of 10 mg on a mg/m2 basis). In another rat study in which male rats were treated with amlodipine besilate for 30 days at a dose comparable with the human dose based on mg/kg, decreased plasma follicle-stimulating hormone and testosterone were found as well as decreases in sperm density and in the number of mature spermatids and Sertoli cells.</p><p>Rats and mice treated with amlodipine in the diet for two years, at concentrations calculated to provide daily dosage levels of 0.5, 1.25, and 2.5 mg/kg/day showed no evidence of carcinogenicity. The highest dose (for mice, similar to, and for rats twice* the maximum recommended clinical dose of 10 mg on a mg/m2 basis) was close to the maximum tolerated dose for mice but not for rats.</p><p>Mutagenicity studies revealed no drug related effects at either the gene or chromosome levels.</p><p>* Based on patient weight of 50 kg</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>Core:</em></p><p>Calcium carbonate starch compound:<em> </em>Calcium carbonate 90%, Pregelatinised maize starch 10%</p><p>Cellulose microcrystalline (E460),</p><p>Croscarmellose sodium (E468),</p><p>Magnesium stearate(E572),</p><p>Colloidal anhydrous silica,</p><p>Pregelatinised starch</p><p><em>&nbsp;</em></p><p><em>Film-coating:</em></p><p>Glycerol (E422),</p><p>Hypromellose 6mPa.s (E464),</p><p>Macrogol 6000,</p><p>Magnesium stearate (E572),</p><p>Titanium dioxide (E 171)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;</p><p>Not applicable</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years

For the container of 28 and 30 film-coated tablet, the in-use stability after first opening is 30 days.
For the container of 100 film-coated tablet, the in-use stability after first opening is 100 days.


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>This medicinal product does not require any special storage conditions</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;</p><p>10, 28 or 30 film-coated tablets in &nbsp;polypropylene &nbsp;tablet container equipped with a low density polyethylene flow reducer and a low density polyethylene stopper containing a desiccant.</p><p>&nbsp;</p><p>100 film-coated tablets in a high density polyethylene tablet container equipped with a polypropylene stopper containing a desiccant.</p><p>&nbsp;</p><p>Box of 10, 28, 30, 60 (2 tablet containers of 30), &nbsp;84 (3 tablet containers of 28), 90 (3 tablet containers of 30), 100, 500 tablets (5 tablet containers of 100).</p><p>&nbsp;</p><p>Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Les Laboratoires Servier
50, rue Carnot
92284 Suresnes cedex– France

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                09.2022
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>